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ABSTRACT
Chemotherapy-Induced Damage of the Bone Marrow Microenvironment
Stephanie Lynne Rellick
The bone marrow microenvironment is characterized as the anatomical site including
specialized niches that support stem cells. In addition, these niches also provide both soluble
and physical cues leading to the differentiation of stem cells into all the cells of the blood. The
studies in this dissertation focus on two supportive niches in the bone marrow
microenvironment, osteoblasts (HOB) and bone marrow stromal cells (BMSC), in the setting of
high dose chemotherapy and the potential damage that chemotherapy treatment causes to the
cells of the bone marrow microenvironment.
In the first study, we investigated the effects of melphalan and Etoposide (VP-16)
treatment on osteoblasts. Previous studies from our lab had shown that chemotherapy
treatment increased the amount of active TGF-β secreted from BMSC, leading to decreases in
the ability to support pro-B cells. Here we describe the novel observation that osteoblasts pretreated with chemotherapy have increased active TGF-β and a decreased capacity to support
human embryonic stem cells (hESC), CD34+ bone marrow derived cells and pro-B cells. We
also evaluated the effects of adding recombinant TGF-β (rTGF-β) to osteoblasts to mimic the
autocrine and paracrine TGF-β in the microenvironment during chemotherapy treatment. rTGFβ treatment of osteoblasts increased TGF-β secretion and also led to a decreased ability to
support hESC, CD34+ bone marrow derived cells and pro-B cells. Microarray analysis of the
cells treated directly with chemotherapy or rTGF-β or conditioned media from BMSC that were
treated with chemotherapy suggested that many genes are changing in response to all of these
treatment groups, indicating that osteoblasts are a vulnerable cell population that can be
affected by high dose chemotherapy, potentially resulting in decreased hematopoietic support.

We also investigated Interleukin-6 (IL-6), a known hematopoietic factor important in both
myeloid and lymphoid differentiation, acute and inflammatory immune responses and bone
metabolism. Neuroendocrine modulation of the bone marrow microenvironment is thought to be
important in both hematopoiesis and immune regulation. We investigated the roles of
neurotrophins in the bone marrow and their effects on BMSC. We show that BMSC express
functional neurotrophin receptors and that treatment of BMSC with two neurotrophins, NGF or
BDNF, led to an increase in IL-6 expression. Increased IL-6 is associated with a number of
inflammatory diseases and our data support the idea that increased neurotrophins in the bone
marrow microenvironment could lead to dysregulated hematopoiesis.
Additionally, we also evaluated the effects of chemotherapy treatment of BMSC and
HOB, focusing on IL-6. Previous data has suggested IL-6 to be involved in graft versus host
disease and we investigated the effects of melphalan on IL-6 expression in BMSC and HOB.
Interestingly, we determined that melphalan treatment led to a decrease in IL-6 mRNA and
protein, and compared to other chemotherapeutic agents used in our studies, melphalan had
the most pronounced effect. We also evaluated the effects of recombinant IL-6 (rIL-6) in
combination with melphalan and determined that the addition of rIL-6 restored both IL-6 mRNA
and protein expression, suggesting that pathways associated with IL-6 expression may be
disrupted. The decrease in IL-6 could potentially affect hematopoiesis and further studies in
vivo need to be completed. Additionally, melphalan is used as first-line therapy in the treatment
of multiple myeloma (MM). IL-6 is a proliferative factor in MM, allowing for disease progression.
The melphalan-induced decrease in IL-6 observed in our studies may, in part, contribute
eradicating the tumor population by decreasing the potent proliferative factor, IL-6.
Collectively, these data contribute to our understanding of alterations to the bone
marrow microenvironment that occur during high dose chemotherapy and emphasize the
importance of understanding the mechanisms that underlie the potential damage leading to
altered ability to support normal hematopoiesis.
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Chapter I

The Bone Marrow Microenvironment as the Site of Hematopoiesis and a
Potential Target of Chemotherapy-Induced Damage

Literature Review

I. Physical components of the bone marrow
Hematopoiesis is the process by which all the cells of the blood are formed.

This

process is dependent on multipotent hematopoietic stem cells (HSCs) which are found in the
bone marrow of adults. The bone marrow microenvironment is characterized as the anatomical
site that includes specialized niches where stem cells are associated with other cells that
influence their behavior1. The function of these niches is to support hematopoietic progenitor
cell proliferation and differentiation, self-renewal and provide a sanctuary for HSCs to remain
quiescent. Spangrude et al described different types of HSCs including both long-term and
short-term repopulating HSCs which were capable of self-renewal and multipotent progenitors
which have very low or no self-renewal capacity2. Human HSCs are characterized by their
surface markers with a phenotype of CD34+, lineage-, CD38-, CD90+ and CD45RA-3. In addition
to self-renewal, HSCs must also be able to differentiate into all the cells of the blood in both the
lymphoid and myeloid lineages.
HSCs have a number of receptors and adhesion molecules that are necessary for
homing, which is the process by which HSCs move through the blood, cross the endothelial cell
layers and take up residence in a variety tissues or the bone marrow, and adhesion in the bone
marrow, which is the physical tethering of HSCs to the adherent, supportive cells of the bone
marrow microenvironment4.

Some examples of these interactions are the presence of the

CXCR4 receptor on the surface of HSCs, which responds to CXCL12, a soluble factor produced
by the bone marrow and osteoblasts to attract HSCs4. Once in the bone marrow, VLA-4 and
VLA-5 on HSCs, interact with VCAM-1 and fibronectin respectively on the surface of bone
marrow stromal cells (BMSC), human osteoblasts (HOB) and bone marrow endothelial cells
(BMEC), mediating cell adhesion and retention in the marrow5.

Some additional signaling

pathways important for maintenance of HSCs in the BM are thrombopoietin (TPO)/Mpl and
Tie2/Angiopoietin-1 (Ang-1)6-8.

The Notch/Jagged and TGF-β signaling pathways will be

discussed later. TPO is a factor that regulates platelet production by binding to its receptor,

2

Mpl, and stimulating the production of megakaryocytes6;9. Recent studies have shown that TPO
signaling may also have important roles in maintenance of quiescence.

Buza-Vidas et al

showed that long-term repopulating HSCs had higher expression of Mpl9, and Qian et al, using
a TPO knock-out mouse, showed that these mice gradually lost HSCs, having a 150 fold
decrease in HSCs, decreased BM cellularity and multilineage defects by one year6.
Additionally, Arai et al showed that TPO was produced by the bone cells in the endosteal niche,
administration of Mpl neutralizing antibody to mice suppressed the quiescence of long-term
repopulating cells and exogenous treatment with TPO restored the quiescent cell population7.
Tie2/Angiopoietin signaling has also been associated with maintenance of quiescence. Arai et
al demonstrated that Tie2 receptors were found on quiescent HSCs and furthermore, these cells
formed a “side population” of cells that were adherent to osteoblasts8. The same group also
showed that osteoblasts produced Ang-1, and that the interaction of Tie2/Ang-1 allowed for
maintenance of long term repopulating HSCs8;10. Some receptors on the surface of HSCs have
important roles in the maintenance of quiescence such as Notch1 and TGF-β receptors11;12. In
order for normal hematopoiesis to occur, HSCs are dependent on the niches in the bone
marrow for support and maintenance of signaling pathways to promote self-renewal as well as
differentiation. These niches are discussed in more detail in the following sections.
The bone marrow has been described as having two hematopoietic support niches that
are anatomically and functionally distinct13;14. These include the endosteal niche consisting of
mesenchymal stem cells, osteoblasts and bone marrow stromal cells (BMSCs)15-17 and the
vascular niche consisting of bone marrow endothelial cells18-20. Each of the cell types within
these niches contribute to hematopoiesis and stem cell regulation through the expression of
cellular adhesion molecules such as VCAM-1 and ICAM-1 and integrins like VLA-4 and VLA-5,
extracellular matrix proteins including collagens, proteoglycans and glycoproteins, and
production of soluble factors including TGF-β and Interleukin-6, which will be discussed in
further detail as a focus of the current study.
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Early studies by Lord and Gong showed that there are higher numbers of colony forming
units (CFU) cells closer to the bone surface than to the center of the marrow cavity21;22. Nilsson
et al and others showed that while most cells enter the bone marrow through blood vessels in
the center of cavity, stem cells are distributed closer to the bone in the endosteal niche, while
committed progenitors were located closer to the center of the bone cavity23;24. The spatial
organization of the niche also correlates with the specific cell types found within it. A precursor
stem cell of osteoblasts and bone marrow stromal cells are mesenchymal stem cells (MSCs)
and they were first characterized by Friedenstein as non-hematopoietic cells that have colony
forming unit-fibroblast (CFU-F) activity, adherence to plastic and the potential to differentiate
into multiple lineages such as osteoblasts, adipocytes, BMSCs and other supportive cells of the
microenvironment25;26. MSCs have a fibroblastic phenotype and express a variety of surface
markers including VCAM-1, Stro-1 and ICAM-127;28.

MSCs are rare in the bone marrow,

reported to represent 1 out of 10,000 nucleated cells29. There are a number of studies that are
examining the idea of co-transplanting MSCs with HSC transplantation30;31. It is thought that
this would help with hematopoietic recovery by providing a pool of supportive microenvironment
cells that could help replace cells damaged by chemotherapy regimens.
One of the major components of the endosteal niche are BMSCs that, in concert with
other components of the microenvironment, support reconstitution of hematopoiesis. BMSCs
are described as fibroblastic reticular marrow cells that are located in the region between the
bone and endothelial niche, also referred to as the subendosteal niche32;33.

Dorshkind

described these cells as “nonhemopoietic, fixed tissue cells in the medullary cavity”34. BMSC
were defined by their ability to form colonies referred to as fibroblast colony forming units25;35.
Another characteristic of BMSC is that they are able to maintain long-term bone marrow
cultures36-39.

These cells, in part, form the cellular network that helps in the regulation of

hematopoiesis. These BMSCs have been characterized as expressing a variety of surface
markers such as VCAM-1 that interacts with VLA-4 on the surface of B cell precursors, allowing
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for their retention in bone marrow40;41. VCAM-1 expression can be regulated through cytokines
present in the marrow. Dittel et al showed that TGF-β had the ability to decrease VCAM-1
protein on the surface of BMSCs while Interleukin-1β and Interleukin-4 can increase VCAM-142.
They also noted a correlation between the amount of VCAM-1 on the surface of the BMSC and
the ability to support B cell precursors. In addition to surface markers, BMSCs also express
extracellular matrix proteins such as collagen I, III, IV, V, VI, fibronectin and laminin and a
number of proteoglycans such as hyaluronic acid and heparin sulfate34;43-45. Another important
component of hematopoietic support is the production and secretion of soluble factors including
SDF-1 (CXCL12), Interleukin-6 (IL-6), IL-3, IL-7, IL-11, granulocyte-macrophage colony
stimulating factor (GM-CSF), stem cell factor (SCF) and flt-3 that not only allow for the homing
of stem cells to the bone marrow but also support the differentiation and maturation of HSCs for
reconstitution of the immune system as well as all the cells of the blood34;46;47. BMSC also
secrete factors that are negative regulators of hematopoiesis such as TGF-β and interferon-γ
(IFN-γ)48;49.
Another critical component of the endosteal niche are osteoblastic cells. There are
different types of osteoblasts. There are spindle-shaped N-cadherin positive (SNO) osteoblasts
as well as osteoblasts that are N-cadherin negative50. Literature has suggested that it is the
SNO cells that line the endosteal surface and that this is the location of the most primitive
hematopoietic cells10;21;22;50;51. One of the main roles of the osteoblastic niche is to maintain
stem cell quiescence, which occurs through both soluble factors as well as cellular adhesion
molecules52;53. Work by Calvi and Zhang showed that osteoblasts are a target of parathyroid
hormone in the bone marrow50;54. In a mouse model where there was expression of osteoblastspecific parathyroid hormone receptor, it was shown that these mice had increased bone mass
and increased numbers of osteoblasts54;55.

Importantly, these transgenic mice also had

increased Jagged1 expression, which is the ligand for the Notch signaling pathway11. This
increased Jagged1 expression also correlated with an increase in HSCs, suggesting that
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osteoblasts have a critical role in the maintenance of Notch signaling and HSC expansion.
Calvi et al also showed that the transgenic mice had increases in the N-cadherin positive
population of osteoblasts11. Another factor secreted by osteoblasts is osteopontin (Opn)56. Opn
has been reported to help HSCs home to the bone marrow and be retained in the endosteal
niche. When HSCs are transplanted into a healthy microenvironment, they reside specifically in
the endosteal regions57.

In an Opn -/- mouse model, HSCs had a random distribution

throughout the bone marrow57. Additionally, Opn-/- mice also had increased BrdU incorporation
in HSCs, suggesting Opn is a negative regulator of HSCs and is important in maintaining
quiescence57.

Osteoblasts have also been characterized as having a number of different

cellular adhesion molecules such as VCAM-1 and fibronectin58.

VCAM-1 is important for

interaction with Very Late Antigen-4 (VLA-4) and Very Late Antigen-5 (VLA-5) interacts with
fibronectin, both of which are found on hematopoietic progenitor cells and can help with homing
to the bone marrow and adhesion once they are in the marrow space58;59.
There is some controversy in the field of osteoblasts as components of the stem cell
niche, specifically related to the presence of N-cadherin and its role in maintenance of stem
cells through homotypic interactions with osteoblasts. Kiel et al did not detect N-cadherin in
purified HSCs using a variety of methods and suggested that it was the N-cadherin negative
population of bone marrow cells that reconstituted irradiated mice60. In a mouse model in which
N-cadherin was conditionally deleted, it was shown that there was no effect on HSC
maintenance or hematopoiesis, as the cellular composition of the bone marrow and the number
of progenitor cells was not affected61. The lack of N-cadherin also did not affect the ability of
HSCs to reconstitute irradiated primary and secondary recipients61. These studies suggest that
N-cadherin expression by HSCs is not essential for regulation of the niche.
Whether N-cadherin is necessary or not has yet to be determined, but osteoblasts are
critical for HSCs to survive and maintain the niche. Work by Visnjic et al showed deficits in
hematopoiesis in mice where osteoblast deficiency was induced. A transgenic mouse model
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with herpesvirus thymidine kinase gene under the control of a collagen alpha 1 type I promoter
allowed for lineage specific expression of the gene in osteoblasts62. These mice lost lymphoid,
myeloid and erythroid progenitors in the bone and had significantly decreased HSCs. When
osteoblasts were allowed to recover, hematopoiesis started to recover in the bone marrow62.
Chitteti et al showed that CFU expansion was increased when HSCs were cultured with
osteoblasts63.

This suggests that osteoblasts have critical roles in the regulation of

hematopoiesis, most likely through both physical and soluble factors.
An additional niche of the bone marrow relevant to stem cell support is the endothelial
niche. The endothelial niche serves as the barrier separating the bone marrow from the blood,
making it a critical component in a healthy bone marrow microenvironment18;64. The main cells
found in this niche are endothelial cells and hematopoietic cells. Both of these cells come from
a common precursor in the embryonic stage called the hemangioblast65. The bone marrow
endothelial cells (BMEC) make a network of thin-walled and fenestrated sinusoidal vessels that
are unique to the bone marrow19. The endothelial niche is important in two different roles within
the microenvironment. The first role is homing to the marrow and allowing HSCs to enter the
bone marrow cavity where the cells then migrate to the endosteal niche18-20;64. The second role
is mobilization and egress of mature cells into the blood4;64.

Prior to entry into the blood,

hematopoietic progenitor cells are supported by both BMSC and BMEC while they mature and
differentiate66;67. The most well studied cell type is the support of megakaryocytes through the
secretion of factors such as FGF-4, SDF-1 and thrombopoietin (TPO), and through adhesion
molecules like VCAM-1 while they mature and differentiate20;68;69. Rafii et al showed the ability
of BMEC to support multi-lineage differentiation68. When hematopoietic progenitors were either
in direct contact with BMEC or in transwells, the progenitors expanded 5-7 fold in one week and
by two weeks in co-culture, 70-80% of the cells were myeloid and 14-19% were
megakaryocytes. They suggested this ability of BMEC to support progenitor cell differentiation
was through the production of cytokines such as IL-6, GM-CSF, G-CSF and Kit-ligand20.
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The physical structure of the bone marrow vasculature has also been studied both in its
support of progenitor cells as well as how progenitor cells can influence the recovery of the
endothelial cells following chemotherapy treatment70. Studies have shown that the integrity of
the vessels is maintained by the surrounding hematopoietic cells, specifically megakaryocytes,
which secrete vascular endothelial growth factor-A (VEGF-A)70.

Following treatment with

cytotoxic agents or radiation, the vessels of the bone marrow are destroyed. Post-treatment,
there is a regeneration of the sinusoidal vessels and this is thought to occur through vascular
progenitors and HSCs that are not affected by the therapy16. One critical protein involved in this
process is MMP-9. Heissig et al showed that MMP-9 led to the release of Kit ligand allowing for
progenitor cells to translocate to the vascular region71. When mice that were MMP-9 deficient
were treated with 5-FU, there was impaired “hemangiogenic” recovery in the bone marrow66.
Additional studies by Avecilla et al showed that using neutralizing antibodies against VEcadherin following 5-FU treatment led to similar effects, including disruption of VCAM-1 and
subsequently the lack of recovery of megakaryocytes66. Other experimental results showing the
close interaction between endothelial cells and HSCs was the identification of stimulated
lymphocyte activating molecules (SLAM) markers on the surface of HSCs72. Kiel et al showed
that more than 50% of HSCs that expressed SLAM markers were found in the vascular region
of the bone marrow, indicating that this niche is a supportive niche of HSCs. Finally, work by
Butler et al demonstrated that HSCs in contact with endothelial cells cultured under serum free
conditions were still able to expand long-term repopulating HSCs both in vitro and in vivo73,
providing further evidence that the endothelial niche is able to support HSCs and
hematopoiesis.
Within all of these niches, there are a vast number of adhesion molecules and cytokines
that must be present and tightly regulated to ensure proper support of hematopoietic stem cells.
We have chosen to focus on the effects of chemotherapy on TGF-β and Interleukin-6 as two
important cytokines in the bone marrow necessary for maintenance of quiescence and
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differentiaion of hematopoietic stem cells.

II. Factors influencing the niche
All of the supportive cells of the BM microenvironment, including BMSC, osteoblasts and
BMEC secrete soluble factors that are critical for the maintenance of quiescence and selfrenewal as well as to promote differentiation of hematopoietic progenitor cells into all the cells of
the blood including lymphoid cells (B cells, T cells and NK cells), myeloid cells (monocytes,
megakaryocytes, macrophages, neutrophils, etc)74.

Chemotherapy exposure of the

microenvironment during pre-transplant regimens has the potential to damage the supportive
cells, and subsequently, can disrupt the secretion of soluble factors necessary for
hematopoiesis. We have chosen to examine the effects of chemotherapy treatment on two of
these soluble factors, TGF-β as a mediator of HSC quiescence, and Interleukin-6 as factor
important in the differentiation of both myeloid and lymphoid progenitors, and both of these
factors and their role in the microenvironment will be described in detail.
A. TGF-β
One soluble factor that is critical in the BM microenvironment is TGF-β, which is secreted by
BMSCs and HOB. TGF-β is a factor that controls proliferation, cellular differentiation, apoptosis
and hematopoiesis12;75. There are three different isoforms, TGF-β1, TGF-β2 and TGF-β3, and
all the isoforms have distinct functions75. TGF-β1 has been shown to inhibit proliferation of
hematopoietic progenitors and stem cells76;77. TGF-β2 has been reported to positively regulate
HSCs77 and TGF-β3 has been shown to have inhibitory effects on progenitors75. TGF-β is a
member of a superfamily of growth factors that are divided into two families which are
characterized both by sequence similarity among members as well as the signaling pathways
that each family activates75. The first family is the TGF-β/ activin/ nodal family which primarily
use Smad2 and Smad3 for signaling75. The second family is the bone morphogenetic protein/
growth and differentiation factor/ Muellerian inhibiting substance and these factors mainly signal
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through Smad1, Smad5 and Smad875. TGF-β signaling occurs through TGF-β receptors on the
surface of cells through a heteromeric receptor complex78.

TGF-β binds to TGF-β Type II

receptors and the Type II receptors then recruit TGF-β Type I receptors and subsequently
phosphorylates serine residues on the cytoplasmic domain.

This then allows for the

phosphorylation of receptor Smads (R-Smads), which are Smads 1, 2, 3, 5 and 879. The RSmads form dimers and then complex with Smad4. This complex then translocates into the
nucleus where it can regulate transcription of target genes. In addition, inhibitory Smads (ISmads) also exist as a way to negatively regulate TGF-β signaling79. I-Smads will compete with
R-Smads for binding to Smad4. I-Smads also tag the receptors for degradation by recruiting
Smurf, an E3 ubiquitin ligase80.
Several studies have shown the role of TGF-β1 in maintaining quiescence of HSCs.
Massague et al showed that TGF-β1 is able to down regulate c-myc, which is a known growth
promoting factor81. Studies by Cheng and Scandura demonstrated the ability of TGF-β1 to
induce cyclin dependent kinase inhibitors, which inhibit cell cycle progression82;83. In addition to
these factors, TGF-β has also been reported to affect the proliferation of HSCs by
downregulating the receptors for granulocyte macrophage colony stimulating factor (GMCSF),
Interleukin-3 (IL-3) stem cell factor (SCF) and IL-684-86. The levels of TGF-β1 in the
microenvironment have been shown to be extremely important. TGF-β at low, physiological
levels is thought to induce CD34 antigen expression on stem cells, and this was sufficient to
maintain hematopoietic immaturity86;87. Pierelli et al supported this finding by demonstrating that
TGF-β1 upregulated both CD34 mRNA and protein88. They showed this led to Smad activation
and decreased phosphorylation of p38, which may be another method of regulation of
quiescence. In addition to maintaining quiescence, Basu et al showed that TGF-β1, at low
levels, modulates SDF-1 responsiveness of CD34+ cells to help with homing to the bone
marrow89. In vivo studies to determine the exact mechanisms by which TGF-β1 regulates
quiescence have been difficult as the TGF-β1 knock-out mouse is 50% embryonic lethal at
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embryonic day (E)10.5 caused by defective hematopoiesis and yolk sac vasculogenesis90;91.
For the mice that do survive, they die after 3 weeks due to inflammatory disease and wasting92.
Yaswen et al were able to show that this defect was something inherent to the HSCs as this
disease is transplantable93. The TGF-βRII knock-out mouse has a phenotype identical to the
TGF-β1 knock-out mouse, suggesting an important role for TGF-β signaling in early embryonic
development94. Capron et al used a conditional TGF-β1 -/- murine model95. These mice had no
evidence of inflammatory disease at 8-10 days and their studies demonstrated that these
animals had impaired short and long term repopulating activity that correlated with decreased
homing, suggesting TGF-β1 has an important role in homeostasis of HSCs, including homing to
the marrow.
While TGF-β may play important roles in maintenance of quiescence, there are also
studies that suggest TGF-β is not necessary in this capacity. Larsson et al used a conditional
knock-out of the TGF-βRI96. In their first study, they showed that the TGF-βRI null mice had
normal hematopoiesis with respect to cell numbers as well as the ability of the progenitor cells
to differentiate.

The HSCs from the TGF-βRI null mice were also able to repopulate both

primary and secondary recipients following bone marrow transplantation. In additional studies,
they treated both knock-out mice and controls with 5-fluorouracil (5-FU) and completed
competitive transplantation assays97. They found no difference in susceptibility of HSCs to
damage and with serial transplants, recipients developed hematopoietic failure at the same
time, regardless of the bone marrow from which they were derived. They suggested this shows
that TGF-β does not maintain the stem cell pool in vivo.
TGF-β is not only involved in regulation of hematopoiesis as it has been implicated in a
variety of other disease settings. TGF-β has been associated with osteoporosis, atherosclerosis
and tissue and organ fibrosis98. TGF-β has also been implicated in cancer. It has been shown
to lead to increases in extracellular matrix production and increases in angiogenesis98;99.
Additionally, TGF-β has been shown to have the ability to be immunosuppressive by
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suppressing infiltrating immune cells100.

B. Interleukin-6
IL-6 as a classic inflammatory cytokine
Another factor of interest to our lab is interleukin-6 (IL-6), as a factor that has important roles in
the hematopoietic system. IL-6 is secreted from both BMSCs and osteoblasts and has both
proliferative and anti-proliferative effects101;102. It is a pro-inflammatory cytokine that is secreted
by T-cells and macrophages in response to tissue injury or pathogens, leading to acute phase
responses and fever101;102. IL-6 also has important roles in bone metabolism by stimulating
osteoclast formation. In the bone marrow microenvironment, IL-6 is important for inducing B-cell
differentiation, stimulation of T-cells103, enhancement of hematopoietic colony formation and the
maturation of megakaryocytes101. IL-6 belongs to a family of cytokines that have redundant and
overlapping signaling pathways due to the use of a common signal transducer, gp130102. IL-6
signaling occurs through a hexameric complex at the cell membrane104.

An IL-6 molecule

interacts with a membrane-bound IL-6 receptor. This interaction leads to an association with
gp130, which is a glycoprotein also found in the membrane that allows for transduction of the
signal105. Upon stimulation with IL-6, gp130 becomes phosphorylated on tyrosine residues106
leading to the activation of signal transducers and activators of transcription (STATs), including,
STAT3. The STAT proteins then interact with members of the Janus Kinase family (JAKs),107
and IL-6 primarily activates JAK1 and STAT3. IL-6 signaling can also lead to the activation of
Ras signaling108.

The signaling cascades that begin in the cytoplasm can then signal to

transcription factors which can enter the nucleus and regulate IL-6 expression. The promoter
region of the IL-6 gene contains response elements that include binding sites for activator
protein-1 (AP-1), Nuclear Factor-IL-6 (NF-IL6) and NF-κB109 that modulate IL-6 transcription.
There are also factors that have been shown to be important in the negative regulation of IL-6
signaling, including Suppressor of cytokine signaling (SOCS) proteins.
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SOCS proteins are negative regulators of cytokine-mediated homeostasis110;111. There
are a number of SOCS proteins but SOCS3 has been shown to be a critical regulator of IL-6. A
SOCS3 knock-out is embryonic lethal and conditional knock-out leads to neutrophilia and
inflammatory diseases, suggesting important roles for the protein in IL-6 associated
inflammatory diseases.
In addition to the membrane-bound IL-6 receptor, a soluble form of the receptor also
exists.

There are two possible mechanisms that have been described that lead to the

production of the soluble IL-6 receptor.

The first mechanism is through differential mRNA

splicing, with the soluble IL-6 receptor lacking the trans-membrane domain112. The second
mechanism suggests that the soluble receptor is produced by cleavage of the membrane-bound
receptor by an endogenous protease, although no endogenous protease has been identified113.
The soluble IL-6 receptor binds to IL-6 molecules with a similar affinity to that of the membranebound receptor and can interact with gp130 on the membrane, leading to IL-6 signaling in the
same manner. Gp130 is ubiquitously expressed throughout the body on a variety of cell types
and tissues. Hibi et al. suggested that the presence of the soluble IL-6 receptor/ IL-6 complex,
and the ubiquitous expression of gp130, may allow cells that would not normally respond to IL-6
to become responsive114. This could potentially lead to a situation of systemic inflammation
similar to graft-versus-host disease.

Interleukin-6 and neurotrophins
In addition to the regulation of hematopoiesis by the supportive cells of the bone marrow
microenvironment, the neuroendocrine system is also thought to play important roles in the
regulation of hematopoiesis and the immune system115. While the most well studied effects of
neurotrophins have been on cells of the nervous system, studies have also shown that cells of
the bone marrow express neurotrophin receptors as well as secrete neurotrophins116. Members
of the neurotrophin family include nerve growth factor (NGF), brain-derived neurotrophic factor
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(BDNF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4) and neurotrophin-5 (NT-5)116.

The

members of the neurotrophin family signal through Trk receptors, which are receptor tyrosine
kinases, on the surface of cells. The Trk receptors include TrkA, which binds NGF, TrkB which
binds BDNF and NT4/5, and TrkC which binds NT-3. There is also a low affinity neurotrophin
receptor p75NTR that has no tyrosine kinase activity but can bind the neurotrophins and interact
with the Trk receptors to enhance or, in some instances, inhibit signaling116.
Studies have shown that NGF has roles in colony formation as well as synergistic effects
with GM-CSF allowing for the differentiation of myeloid cells117. It was also shown that leukemic
cell lines expressed both neurotrophic factors as well as the receptors, suggesting potential
roles for these receptors in normal hematopoietic cells118. NGF has the ability to interact with
other hematopoietic cytokines, such as interleukin-2 (IL-2), where Brodie et al, using B
lymphocytes as a model, showed NGF and IL-2 could increase each other’s receptor
expression119. In a model of stromal cells isolated from the thymus, it was shown that NGF
increased IL-6 expression120. The role of BDNF in hematopoiesis was also studied using a
BDNF knockout mouse121. These mice had reductions in the number of B lymphocytes both in
the spleen and the bone marrow, suggesting this neurotrophin factor has roles in B lymphocyte
development. These data provide strong evidence that factors commonly thought to regulate
cells of the nervous system also have paracrine effects on cells of the hematopoietic system.
Work by our lab has also shown the presence on neurotrophin receptors present on the
surface of BMSC122. BMSC respond to NGF and BDNF by increasing IL-6, and increases in IL6 are associated with a number of inflammatory diseases such as systemic lupus
erythematosus and rheumatoid arthritis118.

The presence of both neurotrophins and their

receptors on BMSC provide a possible mechanism of disruption of normal hematopoiesis if not
tightly regulated (Chapter 2).
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Interleukin-6 deficiency
While most literature on IL-6 focuses on increased levels of IL-6, the interest of our lab is
the impact of an IL-6 deficit in the BM microenvironment. In order to study the different aspects
of IL-6 signaling, a number of transgenic models have been used.

Gp130 knock-out is

embryonic lethal so experiments to study this common signaling receptor use conditional
deletions post-natally123-125. This mutation still led to impaired acute phase immune response,
thrombocytopenia, demyelination of nerves and the development of emphysema. Efforts to
study individual members of the IL-6 family have been more challenging as many of these
family members are redundant in vivo102.

IL-6 knock-out mice are not embryonic lethals,

indicating IL-6 is not critical for embryonic development. However, IL-6 knock-out mice have
hematopoietic deficiencies, decreased acute phase response, defective bone maintenance and
an increase in susceptibility to infections with a variety of different pathogens126;127. It has been
documented that an IL-6 deficient environment decreases DNA synthesis in progenitor cells and
excessive TGF-β production by BMSCs inhibits IL-6 production128;129. Exogenous IL-6 has also
been combined with some radiation therapies because the therapy causes a decrease in IL-6,
and the addition of IL-6 as part of the therapy accelerates hematopoietic recovery130.
Preliminary data from our lab suggests that chemotherapy treatment decreases IL-6 protein in
vitro (Chapter 3). Based on association of IL-6 deficits with sub-optimal hematopoietic recovery,
further investigation of the mechanisms by which chemotherapy alters IL-6 expression is
warranted.

III. Damage of the microenvironment by cancer therapies
Myeloablative chemotherapy and total body irradiation are commonly used to prepare
individuals for bone marrow or stem cell transplantation. While the goal of these regimens is to
eliminate tumor cells, the residual damage to the supportive cells of the microenvironment can
affect the hematopoietic recovery of these patients long-term.
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The earliest studies by

Chamberlin and Fried showed the effects of radiation and chemotherapy on hematopoietic
stromal cells131;132. In their studies, they observed that the hematopoietic cells (CFU) were able
to recover, while the hematopoietic stroma did not recover in models where damaged femurs
were transplanted into isogeneic hosts.

It is well documented that chemotherapy induces

stromal cell damage. Patients receiving standard chemotherapy regimens had a reduced
capacity to form confluent monolayers when BMSCs were isolated from aspirates133. Stromal
cells damaged by chemotherapy and radiotherapy can affect the ability of the BMSCs to selfrepair and can also lead to chronic states of osteoporosis by altered bone metabolism as well as
a decreased number of functional mature cells in the blood134;135. Galotto et al demonstrated
that patients receiving allogeneic bone marrow transplants have serious and irreversible stromal
damage as measured by CFU-F frequencies that did not recover to the levels of normal control
patients even after 12 years136. They reported that CFU-F frequencies were reduced by 60-90%
in bone marrow transplant patients.

In another study, damage of the bone marrow was

evaluated using cell culture assays137. One year post-treatment, bone marrow samples were
isolated from normal donors or patients that had received peripheral blood stem cell
transplantation for a variety of different cancers including breast cancer, non-Hodgkin lymphoma
and Hodgkin lymphoma. The samples were analyzed using colony forming assays and long
term bone marrow cultures (LTBMCs).

They determined that the numbers of committed

progenitors were significantly reduced in all the groups that had received prior treatment. A
healthy stromal cell compartment should have cobblestone areas, adipocytes and support
colony formation. The LTBMCs also showed that the adherent layer of cells from patients
treated with chemotherapy did not have these properties and could not support progenitor
cells137.
Damage to MSCs, which have the ability to differentiate into multiple cell types such as
osteoblasts, adipocytes or BMSC, have also been studied to understand how damage to the
cells that can “reconstitute” the supportive cells of the bone marrow are affected by
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chemotherapy and how hematopoietic recovery might be affected by this damage. Kemp et al
evaluated MSCs and how this population of cells is affected by high dose chemotherapy31.
MSCs from patients with hematological malignancies were characterized and compared to
untreated patients.

It was shown that the MSCs isolated from patients with hematological

malignancies were not able to expand in culture, making them unable to be stimulated to
determine if the cells had the capacity to differentiate into different cell types. The cells also had
decreased CD44 staining, which is a cellular adhesion molecule important for MSC interaction
with HSCs. These data suggest that co-transplantation with MSCs may be beneficial.
Many efforts have been made to determine ways to help patients receiving transplants
have more rapid hematopoietic recovery.

Some of the first factors investigated were

recombinant human GM-CSF and G-CSF138. The use of these factors showed increases in
neutrophils and in a trial by Klumpp et al, it was demonstrated that administering G-CSF led to
significant decreases in time to neutrophil engraftment, and the patients had decreased hospital
stays, decreased treatment with antibiotics and a more rapid myeloid recovery139.
Erythropoietin (EPO), another hematopoietic factor that controls red blood cell production and is
commonly administered to patients to help with recovery from anemia138. IL-6 was investigated
to determine if giving it to patients post-transplant would help promote immune system
recovery140. This cytokine did provide some moderate effects by increasing megakaryopoiesis
and thrombocytopoiesis, the cytotoxic effects, including fevers, chills, fatigue, anemia and
erythema have made clinicians cautious about use of the cytokine post-transplant.

Some

groups have also evaluated administering factors during chemotherapy to aide in hematopoietic
recovery. Matrosova et al demonstrated that 5-fluorouracil (5-FU) decreases hyaluronic acid
(HA) in the bone marrow and HA has been shown to be important for hematopoiesis in vitro141.
Mice given HA while being treated with 5-FU displayed a more rapid recovery of hematopoiesis.
They showed increased hematopoiesis in the bone marrow of these mice, suggesting not only
that HA had important roles in hematopoiesis but also that administering factors may help with
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hematopoietic recovery. While a variety of hematopoietic factors have been investigated to help
with hematopoietic recovery, no individual factor or combination of factors has been identified
that allows complete hematopoietic recovery.
TGF-β, as an important factor in the microenvironment for maintenance of quiescence,
has been previously described. Although there are many studies that address the effects of
chemotherapy on TGF-β, most of them describe increases in TGF-β as a negative prognostic
factor. In several reports, it has been documented that chemotherapy can lead to an increase
in TGF-β levels. In a study by Butta et al, it was demonstrated that Tamoxifen led to an
induction of TGF-β1 as seen in biopsy samples from patients with breast cancer142.
Furthermore, TGF-β inhibitors are currently being used in both pre-clinical and clinical trials as
well as neutralizing antibodies as a method to reduce cancer progression and to aid in
hematopoietic recovery143. TGF-β is also being used as a prognostic factor in radiotherapy for
non-small cell lung cancer to determine which patients can receive escalated therapy. The
higher the TGF-β levels were in the patient, the greater the toxicity144. In a different cancer
setting, it was shown that chemotherapy treatment for Acute Lymphoblastic Leukemia led to
increased TGF-β levels, decreased ability of stromal cells to support hematopoiesis, and posttreatment anemia145.

Based on the data describing increases in TGF-β in response to

chemotherapy, one could deduce that this increase in TGF-β detrimentally affects the stem cell
population in the bone marrow.
Collectively, these observations emphasize the microenvironment as a site that is
vulnerable to change imposed by diverse treatments.

The dynamic nature of the

microenvironment is reflected, in part, by fluctuation in soluble factors produced by
microenvironment cellular components. Our model of chemotherapy-induced stromal damage,
uses the chemotherapeutic agent melphalan, with VP-16 included in some experiments as an
agent we have characterized to some degree previously. VP-16 (Etoposide) is a topoisomerase
II inhibitor, which leads to strand breaks in the DNA making it a popular anti-cancer agent. It
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has been used in Ewing’s sarcoma, lung cancer, lymphoma, leukemia and in pre-transplant
regimens before bone marrow or stem cell transplants. Melphalan belongs to the nitrogen
mustard DNA alkylating class of drugs. Its mechanism of action is to add alkyl groups to the
guanine residue in DNA. Melphalan is currently used as front-line therapy for the treatment of
multiple myeloma, ovarian cancer, breast cancer as well as being used as part of a pretransplant chemotherapy regimen for autologous stem cell and allogeneic stem cell
transplantations, making it a clinically relevant agent for our experiments146;147.

Studies by

Down et al showed that melphalan was more toxic to early developing cobblestone area-forming
cells. In this study, mice were treated with melphalan or a number of other chemotherapeutic
agents for 24 hours and the marrow compartment was isolated from femurs. Early and late
cobblestone areas were then established in culture148.
Based on all these data, more studies are necessary to understand the mechanisms by
which high dose chemotherapy regimens lead to damage of the supportive components of the
bone marrow microenvironment and how this damage leads to a decreased capacity to support
both HSCs and hematopoietic progenitor cells.
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Figure 1. Architecture of the bone marrow microenvironment.
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Figure 2: Bone marrow microenvironment and cell differentiation
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Figure 3: Hematopoietic hierarchy and characterization of stem cell markers
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Figure 4: Soluble factors involved in cell differentiation
Molecular cell biology. Lodish, Harvey F. 5. ed. : - New York : W. H. Freeman and
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Figure 5: HSC interaction with endosteal and vascular niches
Yin T and Li L. 2006. The stem cell niches in bone. J. Clin. Invest.
American Society for Clinical Investigation permission number: 47232685
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Abstract :
Hematopoietic reconstitution, following bone marrow or stem cell transplantation, requires a
microenvironment niche capable of supporting both immature progenitors and stem cells with
the capacity to differentiate and expand. Osteoblasts comprise one important component of this
niche. We determined that treatment of human primary osteoblasts (HOB) with chemotherapy
resulted in increased phospho-Smad2, consistent with increased TGF-β activity. This increase
was coincident with reduced HOB capacity to support immature B lineage cell chemotaxis and
adherence. The supportive deficit was not limited to committed progenitor cells, as human
embryonic stem cells (hESC) or human CD34+ bone marrow cells co-cultured with
chemotherapy or rTGF-β pre-treated HOB had profiles distinct from the same populations cocultured with untreated HOB. Functional support deficits were downstream of changes in HOB
gene expression profiles following chemotherapy. Chemotherapy induced damage of HOB
suggests vulnerability of this critical niche to therapeutic agents frequently utilized in pretransplant regimens and suggests that dose escalated chemotherapy may contribute to posttransplantation hematopoietic deficits by damaging structural components of this supportive
niche.
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Introduction:
The stem cell niche hypothesis was first presented in 1978 by Schofield who suggested
that stem cells were associated with accessory cells that influence their behavior 1. Studies
from several labs have expanded our appreciation of the unique anatomical niches within the
marrow microenvironment and have characterized areas of optimal stem cell support 2. The
niche’s cellular components consist of osteoblasts (HOB), bone marrow stromal or
mesenchymal stem cells (BMSC, MSC), and endothelial cells 3;4. Recent work has
demonstrated the importance of the interaction of osteoblasts and stem cells in the niche,
suggesting that hematopoietic stem cells (HSC) can regulate MSC differentiation into
osteoblasts and that they, in turn, play an important role in the support of B lymphocytes and
differentiation of HSC 5;6. Additionally, it has been shown that resting HSC are maintained in a
quiescent state as a result of their close proximity to osteoblasts and that the number of HSCs
change as a result of the number and type of osteoblasts present 7;8. Studies describing BMSC
have shown that damage by chemotherapy and radiotherapy can affect the ability of the BMSC
to self-repair and leads to decreased numbers of functional immune system cells in the blood,
with deficits persisting years after transplant 9;10. The effects of chemotherapy on osteoblasts,
and subsequently HSC and progenitor cell support, have not been as well characterized as
those on BMSC, and warrant further investigation.
The stem cell niche is characterized, in part, by expression of specific cytokines,
including TGF-β and CXCL12, to facilitate signaling between the niche components and HSC.
Studies have demonstrated that chemotherapy increases the levels of active TGF-β resulting in
decreased ability of BMSC to support HSC 11;12. It has also been shown that TGF-β has
crosstalk with CXCL12 and can stimulate the differentiation of progenitor cells to erythroid and
myeloid cells resulting in a deficit of the primitive stem cell pool13. The importance of CXCL12 is
demonstrated by its requirement for homing of progenitor cells to the bone marrow following
transplantation 14;15. We have previously demonstrated that diminished levels of CXCL12 in the
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supernatants of VP-16 treated BMSC results in loss of an optimal chemokine gradient to which
CXCR4+ pro-B cells respond with CXCL12 subsequently shown to also be important in
regulation of stem cell phenotype by Guo et al.

16;17

. Sugiyama et al showed that mice deficient

in the CXCL12 receptor, CXCR4, had a reduction in HSC, in both vascular and endosteal
niches, and increased sensitivity to myelotoxic stress compared to their wild-type counterparts
18

. Other studies of CXCR4 in the HSC niche have shown that CXCR4 is essential to maintain

quiescence and retention of stem cells 19. In the current study, we investigate chemotherapymediated damage of osteoblasts with emphasis on CXCL12 and TGF-β levels following
chemotherapy. Global changes in HOB gene expression in response to melphalan were
investigated to determine the vulnerability of osteoblasts to genotoxic stress. In addition, TGFβ, CXCL12 and VCAM-1 were investigated as representative osteoblast proteins involved in
three critical functions of the endosteal niche; support of pluripotency, homing and stem cell
retention 20;21. Our results indicate diverse changes in gene expression profiles following HOB
exposure to melphalan, conditioned media from BMSC pre-treated with melphalan, and
following exposure to rTGF-β as one of the factors elaborated by chemotherapy damaged
stroma 11. Coincident with altered gene expression profiles treated HOB had increased levels of
active TGF-β, reduced ability to support Oct-4 positive embryonic stem cell colonies, deficits in
support of differentiation of CD34+ bone marrow cells, and reduced chemotactic support and
adhesion of CXCR4+ pro-B cells. These data suggest that the niche in which hematopoietic
recovery occurs may be more vulnerable to damage than previously appreciated.

Materials and Methods:
Cell Lines and Reagents
Human osteoblasts (HOB) were purchased from Promocell (Heidelberg, Germany) and
maintained in osteoblast growth media. The CXCR4+/VLA-4+ pre-pro-B leukemic cell line JM-1
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was purchased from the ATCC (CRL-10423, Manassas, VA). The BMSC and IL-7 dependent
murine pro-B cell line C1.92 was kindly provided by Dr. Kenneth Landreth and has been
described in detail 22. Human embryonic stem cells (H9, WiCell, Madison WI) were maintained
on irradiated mouse embryo fibroblasts (MEF) and grown in DMEM-F12 media (Mediatech,
Manassas, VA) supplemented with Knockout Serum Replacement (Gibco/Invitrogen, Carlsbad,
CA), 2 mM L-glutamine (Mediatech), 0.05 µM 2-mercaptoethanol (Sigma-Aldrich, St. Louis,
MO), non-essential amino acids and B-FGF solution. H9 cells were moved to HOB feeder
layers where indicated. CD34+ bone marrow cells (ALLCELLS, Emeryville, CA) were grown in
RPMI-1640 supplemented with 10% fetal bovine serum. Melphalan (Sigma-Aldrich) was
reconstituted at a stock concentration of 2.5mg/ml or 50mg/ml immediately prior to use. VP-16
(Etoposide, Bristol Myers Squibb, New York, NY) was stored at a concentration of 33.98mM and
diluted immediately prior to use. Human rTGF-β (R&D, Minneapolis, MN) was used at a
concentration of 10ng/ml. In all experiments that include rTGF-β, it was added to the culture
every 6 hours based on its short half-life. Human rIL-3 (R&D) was used at a concentration of
100 ng/ml.

Adhesion Assay
HOB were pre-treated with 50μg/ml melphalan, 50µM VP-16, or 10ng/ml rTGF-β for 24
hours. C1.92 pro-B cells were stained with CellTracker Green (Invitrogen) according to the
manufacturer’s instructions. The HOB adherent layer was thoroughly rinsed following treatment
and 1x105 fluorescently labeled C1.92 pro-B cells were added in co-culture for 24 hours.
Subsequently, the media containing non-adherent C1.92 was aspirated and the cultures were
gently rinsed. Remaining HOB and adherent C1.92 were trypsinized and C1.92 cells were
enumerated using a FACSCalibur flow cytometer (BD, Franklin Lakes, NJ) with events counted
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for 30 seconds on high flow rate. Data were analyzed using WinMDI software.

Chemotaxis Assays
HOB were plated in the bottom chamber of a transwell at 100% confluence and were left
either untreated or treated with 50 µg/ml melphalan, 50 µM VP-16, or 10 ng/ml rTGF-β for 24
hours. After 24 hours, 350 µL of supernatant was placed in the bottom of a transwell and JM-1
cells (1x106 cells/mL) were added to the top chamber, and incubated at 37°C for 4 hours. JM-1
cells migrated through the 5µm pores to the bottom chamber towards media supplemented with
100 ng/mL CXCL12 (positive control), towards media alone (negative control), or towards media
conditioned by the chemotherapy treated or non-treated HOB. Cells were collected using a
FACSCalibur flow cytometer (BD) with events counted for 30 seconds on high flow rate. Data
were analyzed by WinMDI software.

ELISA
To complete the CXCL12 ELISA (R&D), HOB were plated at 100% confluence in a 96
well plate and left untreated or treated with 10 ng/ml rTGF-β, 50 μg/ml melphalan or 50 μM VP16 for 24 hours. The media was then removed, cells were rinsed and fresh serum-free media
was added to each well. Following 24 and 48 hours of incubation supernatants were collected
and analyzed for CXCL12 following the manufacturer’s instructions. The TGF-β ELISA (R&D)
was completed using HOB plated at 100% confluence in serum free media and left untreated or
treated with 10 ng/ml rTGF-β, 50 μg/ml melphalan or 50 μM VP-16 for 24 hours. The media was
removed, cells were rinsed, and fresh serum-free media was added to each well. After 24 and
48 hours supernatants were collected and analyzed for TGF-β following the manufacturer’s
instructions.
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Fluorescent Microscopy
HOB cells were cultured on coverslips and left untreated or treated with 50 µg/ml
melphalan, 50 µM VP-16, or 10 ng/ml rTGF-β for 24 hours, washed thoroughly and H9 stem
cells added. Stem cell colonies were monitored for 2 days and counts based on colony
morphology were completed. Cells were subsequently stained for Oct-4. To complete
intracellular staining, cells were fixed in 4% paraformaldehyde and permeabilized with 0.5%
Triton X-100. After blocking for 30 minutes in 5% BSA/1X PBS, cells were incubated with
mouse primary antibody (1µg) specific for human Oct-4 or the matched isotype control, in 5%
BSA/1X PBS for 1 hour at RT. Coverslips were washed with 1X PBS, incubated with Alexa
Fluor 488 labeled secondary α-mouse antibody (1 µg) at RT for 1 hour and mounted on glass
microscope slides with ProLong Gold plus DAPI (Invitrogen). Confocal images were acquired
using a Zeiss LSM510 confocal system connected to a Zeiss AxioImager microscope
(Thornwood, NY). Photographs of human embryonic stem cells were taken using a Nikon
Coolpix 990 camera. To complete phospho-Smad2 staining, HOB cells were plated on
coverslips and left untreated or treated for 4 hours with 100 µg/ml melphalan, 100 µM VP-16, or
with conditioned media from BMSC that were untreated or treated with 100 µg/ml melphalan or
100 µM VP-16 for 24 hours. Staining and imaging was completed as described above using a
murine primary antibody (1.5 µg/coverslip), specific for human phospho-Smad2 (Cell Signaling
Technology Inc., Danvers, MA) or matched isotype control.

Microarray
HOB cells were left untreated, or treated with 50µg/ml melphalan, 10ng/ml rTGF-β or
conditioned media from BMSC (treated with 50µg/ml melphalan for 24 hours) for 6 hours. Total
RNA was isolated from HOB using the RNeasy RNA isolation kit (Qiagen,Valencia, CA) with
quality assessed by electrophoretic analysis on an Agilent Model 2100 Bioanalyzer. RNA
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samples had integrity numbers greater than 8.0 (8.4-10). RNA (250 ng) was used as the
template for synthesis of internally labeled cRNAs using the Agilent QuickAmp Labeling kit and
cyanine 3-CTP and cyanine 5-CTP (Perkin Elmer, Waltham, MA) and a modified QuickAmp
protocol 23. A total of 825 ng of cyanine 3- and cyanine5-labeled cRNAs was combined and
hybridized onto Agilent Whole Human Genome 4 x 44 K microarrays at 65oC for 17 hours and
washed according to the manufacturer’s protocol. Slides were scanned on an Agilent DNA
Microarray Scanner. HOB treated with rTGF-β and conditioned media were competitively
hybridized against untreated HOB in a balanced block design with six replicates. Melphalan
treated HOB and untreated HOB were hybridized against Stratagene Universal Reference RNA
(Agilent Technologies, Santa Clara, CA) in a universal reference design with four replicates.
Intersections of groups and corresponding statistically significant fold changes (details
described in the supplemental section) for each experiment were imported into Ingenuity
Pathway Analysis (IPA) software v 2.6 (Ingenuity Systems ®, Redwood City, CA,
www.ingenuity.com). We performed a core analysis in IPA, using default settings, to search for
networks associated with these lists of genes. Complete microarray data may be accessed at
the NCBI Gene Expression Omnibus (GEO) database (GSE17860).

Real Time Reverse Transcriptase PCR
Total cellular RNA was isolated from HOB using the RNeasy RNA isolation kit (Qiagen).
Real time RT-PCR was performed using 50ng RNA per reaction using the QuantiTech SYBR
Green RT-PCR kit supplied by Qiagen. Primers specific for human CXCL12 were obtained from
SuperArray (Frederick, MD) with 0.25µl used per reaction. Primers specific for TGF-β and the
housekeeping gene (HPRT-1) were purchased from Real Time Primers, LLC (Elkins Park, PA).
Samples were analyzed in triplicate using the Applied Biosystems 7500 Real-time PCR system
(Foster City, CA). Amplification parameters included 50°C for 30 minutes, 95°C for 15 minutes,
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94°C for 15 seconds (x 45 cycles), 58°C for 30 seconds, and 72°C for 45 seconds. Changes in
gene expression were determined using the Comparative Ct method and analysis of relative
gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

HOB and CD34+ cell co-culture
HOB were grown to confluence and were either untreated or treated with 25ug/ml
melphalan or 10ng/ml rTGF-β1 for 24hrs. Following treatment, the cells were rinsed and
human CD34+ bone marrow cells were added. Cultures were supplemented with recombinant
IL-3 (100ng/ml) every 2 days. CD34+ bone marrow cells were collected 2 and 6 day post coculture. Viability was determined and staining for the following cell surface makers was
completed using the indicated antibodies: phycoerythrin (PE)–conjugated CD4 (clone SK3),
CD19 (4G7), phycoerythrin-Cy7 (PE-Cy7)–conjugated CD56 (NCAM16.2), CD34 (8G12),
peridinin-chlorophyll protein-Cy5.5 (PerCP-Cy5.5)–conjugated CD3 (SK7), CD33 (P67.6),
fluorescein isothiocyanate (FITC)–conjugated CD8 (SK1), CD71 (L01.1), allophycocyanin
(APC)–conjugated CD14 (MφP9), CD3 (SK7), and allophycocyanin-Cy7 (APC-Cy7)–conjugated
CD45 (2D1) ([BD], San Jose, CA). The samples were stained in the following combinations:
isotype controls and CD45, CD45, CD34, CD3, CD19, CD33, and CD71 and CD45, CD3, CD4,
CD8, CD56, and CD14. Data were acquired with a FACSCanto II (BD) flow cytometer with a
minimum of 30,000 events for each sample and analyzed with FACSDiva software (BD). Initial
gating was based on forward (FSC)/ side scatter (SSC) to exclude debris and non-viable
events. Thresholds for positivity were set such that greater than 99% of events within the gated
region were negative for each isotype-matched control antibody. Positive events were backgated to ensure that they constituted a discrete population by CD45/SSC, confirming specificity
of antigen binding.
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Statistics
Data were analyzed using the Students–t test or ANOVA where appropriate with
statistical significance of p≤.05 denoted by an asterisk (*). Microarray data analysis is described
in the supplemental section.

Results
Melphalan, or factors from chemotherapy damaged BMSC, affect TGF-β pathways in
HOB.
Earlier observations have demonstrated that BMSC exposed to chemotherapy have
higher levels of active TGF-β and diminished capacity to support pro-B cells and normal
hematopoiesis 11-13;24. Additionally, retrospective studies of patients that received allogeneic
bone marrow transplants showed that they have serious and irreversible stromal damage as
measured by CFU-F frequencies that did not recover to the levels of normal control patients
even after 12 years, suggesting that the damage done to the supportive cells of the bone
marrow is irreversible 25.
To determine if direct chemotherapy damage to HOB cells results in increased active
TGF-β, HOB were treated with melphalan or VP-16 and the expression of total and active TGFβ was assessed. Direct exposure to chemotherapy (Figure 1A) does not alter the expression of
TGF-β mRNA but does result in increases in active TGF-β capable of signaling, reflected by
increased phosphorylation of Smad2 protein. However, direct treatment with rTGF-β (Figure 1
B) increases both TGF-β mRNA and protein expression. To mimic the indirect effects of soluble
cues elaborated by damaged stroma on HOB, BMSC were treated with melphalan or VP-16,
rinsed, and allowed to condition media that was then placed on HOB that had not been exposed
to chemotherapy. HOBs exposed to conditioned media from damaged BMSC have higher levels
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of phosphorylated Smad2 than their counterparts exposed to conditioned media from untreated
stroma (data not shown).

Chemotherapy or rTGF-β diminishes HOB support of human stem cells and adhesion of
pro-B cells.
One of the critical functions of osteoblasts in the endosteal niche is to support stem cells,
and post-transplantation, osteoblasts are crucial to efficient and sustained hematopoietic
reconstitution 26. Therefore, we investigated how chemotherapy or rTGF-β modulates the ability
of osteoblasts to support human stem cells. Figure 2 shows that in the absence of treatment,
osteoblasts support undifferentiated stem cell colonies characterized by morphology of dense
round colonies with definitive, regular, cell borders. In contrast, after HOB pre-treatment with
melphalan, VP-16 or rTGF-β, there is an increase in the number of differentiated stem cell
colonies with irregular borders (Figure 2A). Oct-4 staining was completed on stem cell colonies
as a measure of pluripotency potential, with a decrease in the ability to support Oct-4 positive
colonies observed in HOB that had been pre-treated with chemotherapy or rTGF-β (Figure 2B).

Pre-treatment of HOB with rTGF-β or melphalan changes the differentiation pattern of
CD34+ cells.
We next investigated the effects of these treatments on the ability of HOB to support
CD34+ hematopoietic stem/ progenitor cell self-renewal and lineage differentiation. Figure 2C
summarizes observations indicating that following exposure to rTGF-β or melphalan, distinct
differentiation patterns of CD34+ bone marrow cells was supported. Deficits in total
lymphocytes, with specific alteration of B cell and NK cell differentiation were seen subsequent
to treatment. T-cells represented 0.1% of the lymphocyte cell population in the untreated group,
while no T cells were detected in cultures that included HOB treated with rTGF-β or melphalan
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(data not shown). Additionally, melphalan treatment of HOB leads to a decreased granulocyte
population, while exposure to rTGF-β enhances granulocyte differentiation and both rTGF-β and
melphalan decreased erythrocyte progenitors. There was no change in monocytes with rTGF-β
treatment and a slight decrease in monocytes with melphalan treatment (data not shown) and
viability among all groups was similar (82-87%). Taken together, these data suggest that
exposure of HOB to direct and indirect chemotherapeutic damage has functional consequences
with respect to support of hematopoietic differentiation.
Alterations in osteoblast function after aggressive treatment could impact transplant
engraftment and hematopoietic reconstitution 8;20. For technical ease we utilized CXCR4+/VLA-4+ C1.92 and JM-1 pro-B cells to investigate the effects of chemotherapy on the ability
of HOB to support immature hematopoietic progenitor cell adhesion and chemotaxis.
Experiments summarized in Figure 2D indicate that following HOB pre-treatment with
chemotherapy or rTGF-β, C1.92 pro-B cells did not adhere as efficiently as they did to untreated
controls. To determine if alterations in adhesion molecule expression were associated with
decreased adhesion between C1.92 and HOB, VCAM-1, CD44 and Hyaluronan expression
were evaluated on the HOB in the presence and absence of chemotherapy. No modulation of
these proteins was detected on the HOB during chemotherapy exposure (data not shown).

Chemotherapy or rTGF-β diminishes HOB expression of CXCL12.
Inhibition of CXCL12 in the bone marrow has been shown to have a negative impact on
chemotaxis leading to deficits in HSC homing and engraftment 14;27. To further investigate the
impact of chemotherapy and rTGF-β treatment on expression of osteoblast derived CXCL12,
real time RT-PCR and ELISA were completed as described. Pre-treatment of HOB with
chemotherapy or rTGF-β decreased the amount of CXCL12 mRNA and protein detected by real
time RT-PCR and ELISA, respectively (Figure 3A and B). Jung et al have described how the
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regulation of SDF-1 by osteoblasts can affect homing and reported that treatment of osteoblasts
with TGF-β decreased SDF-1 secretion which is consistent with our results 28. Additionally, as a
functional readout of a potential CXCL12 deficit in our model, chemotaxis of JM-1 cells toward
HOB that were untreated or pre-treated with chemotherapy or rTGF-β was completed. Figure
3C summarizes data indicating that chemotaxis of JM-1 cells toward adherent layers of HOB
was impaired by melphalan or rTGF-β treatment.

Direct and indirect chemotherapy induced damage results in global changes in HOB
gene expression.
To elucidate the global changes that occur in osteoblasts with direct and indirect insult
from chemotherapy, HOB were exposed to either rTGF-β or melphalan. In addition, HOB were
exposed to conditioned media from BMSC that had been pre-treated with melphalan (drug
removed prior to collection of conditioned media) to recapitulate signaling that may occur in
response not only to active TGF-β elaborated by BMSC, but also in response to the collective
soluble factors elaborated by BMSC in response to chemotherapy induced stress. Microarray
analysis of gene expression was performed as described. The genes for which expression
changed in each group individually, and common gene targets that overlap between treatment
groups, are indicated in the Venn diagram (Figure 4A). HOB exposure to recombinant TGF-β
resulted in the highest number of genes influenced across the treatment groups evaluated, with
melphalan exposure also resulting in a robust effect. Twenty-five common genes significantly
changed when the intersection of all treatment groups was considered. The Venn and network
diagrams show the number of genes modulated due to treatment, and potential relationships
between some of the responsive genes, as well as convergence on signaling molecules such as
the NF-κB complex which emerged as a hub of signaling. The genes that were commonly upregulated (red) or down-regulated (green) between treatment groups are shown and include: 4
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up-regulated, 2 down-regulated (Figure 4, intersection of all 3 treatments), 16 up-regulated, 3
down-regulated (Figure S1, CMM: melphalan), 26 up-regulated, 11 down-regulated (Figure S2,
rTGF:CMM), and 97 up-regulated, 188 down-regulated (S3, rTGF: melphalan). This summary
can be compared with those genes that were influenced, but in opposing directions, between
groups (S4).

Discussion
Myelosuppressive and ablative therapies followed by stem cell transplantation is used to
treat hematopoietic, breast, ovarian and brain tumors as well as childhood sarcomas, and
immune deficiencies 29;30.

As the primary site of postnatal hematopoiesis, the functional

integrity of the bone marrow microenvironment is critical for hematopoietic recovery. Earlier
reports have suggested that BMSC are vulnerable to functional damage imposed by aggressive
chemotherapeutic agents 12;13;31. These studies have focused largely on the ability of stromal
cells to generate fibroblastic colonies (CFU-F) or to support survival or expansion of committed
progenitor cells when isolated from patients following treatment of subsequent to in vivo drug
exposures 32.
Murine models of ablative treatment and stem cell transplant have shown long-term
deficits in hematopoietic recovery and in vitro models have paralleled these documenting the
inability of transplanted cells to migrate efficiently to the necessary anatomical niches for
engraftment 33. Observations of long-term hematopoietic deficits in bone marrow of
transplantation patients suggest that the functionality of the developmental niches required for
appropriate support of immature hematopoietic or stem cells may have been compromised by
aggressive pre-transplant therapies. One study observed that at 1 year post transplant 61% of
patients have subnormal values in one or more hematopoietic lineages 34. Further, Nieboer et
al. showed that at 5 years post transplant 15% of the patient population analyzed had low
values in one or more hematopoietic cell lineages 35. Investigation of the mechanisms that
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underlie damage of the hematopoietic and stem cell niche is further encouraged by
retrospective studies of patients that received allogeneic bone marrow transplants in which
patient HSC did not recover to the levels of control patients, even after 12 years, as measured
by CFU-F frequencies, suggesting that the damage of the structural, hematopoietic supportive
cells of the bone marrow can be sustained 36.
In the current study we characterized the impact of direct and indirect damage on
osteoblasts and their subsequent ability to support progenitor and stem cells. Following
transplantation and during development, HSC home to the endosteal niche which acts as a
critical regulator of stem cell quiescence, proliferation, and conservation of the stem cell pool.
Direct contact between osteoblasts and HSC is required for HSC survival 7;8;37 with a dynamic
relationship demonstrated by the ability of HSC to regulate the cytokines expressed by
osteoblasts in order to enhance their own survival. Studies by Calvi et al., and others, have
shown that number of osteoblasts present in the niche directly modulates the numbers of HSC
that can be supported by the niche 7;8;20.
Our data has shown that both direct exposure to chemotherapy as well as exposure to
conditioned media from chemotherapy damaged BMSC increases the activity of osteoblast
derived TGF-β, one of the known negative regulators of HSCs (Figure 1) 11-13. Consistent with
the literature suggesting that TGF-β activity leads to decreased expression of HSC surface
cytokine receptors and a deficit in the stem cell pool,13;38 Figures 2 and 3 summarize data that
show the decreased ability of chemotherapy damaged osteoblasts to interact with, and support,
both human embryonic stem cells as well as more differentiated pro-B cells. Direct treatment of
HOB with active TGF-β results in a comparable reduction in pro-B cell adhesion and chemotaxis
as well as diminished ability to support Oct-4 positive stem cells. In addition, HOB pre-treated
with either rTGF-β or melphalan had a decreased ability to support differentiation of CD34+
bone marrow cells. Deficits occurred in the lymphocyte population, with decreased B cells, NK
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cells and T cells in addition to decreased erythroid and granulocyte progenitors. Collectively,
these data suggest that chemotherapy induced increases in active TGF-β, from damaged
BMSC and HOB, could contribute to deficits in the reconstitution of the hematopoietic niche.
Another consideration when evaluating the dynamic balance of the niche is the role of
adhesion molecules physically tethering progenitor cells to supportive cells of bone marrow,
which provides signals for their maturation and survival. Earlier reports have described the role
of the VCAM-1/VLA-4 interaction in hematopoiesis. Ryan et al demonstrated that adhesion of B
cell precursors to BMSC was dependent on this interaction and Dittel et al elucidated how
cytokines could alter the surface expression of VCAM-1 39;40.
In addition to the VCAM-1/ VLA-4 interaction, the CD44/ hyaluronan (HA) interaction has
also been recognized for its role in hematopoiesis and homing of primitive cells to the bone
marrow 41. Avigdor et al demonstrated the important roles of CXCL12 with respect to the
migration and anchorage of progenitors to the bone marrow through CD44/ HA 42. It was based
on these observations that we investigated the effects of chemotherapy on VCAM-1, CD44, and
HA in our model of osteoblast damage. Figure 2D shows that pro-B cells co-cultured with
chemotherapy or rTGF-β pre-treated osteoblasts are unable to adhere to the osteoblasts
efficiently. However, investigation of the adhesion molecules VCAM-1, CD44 and Hyaluronan
indicated no altered expression following either chemotherapy or rTGF-β exposure (data not
shown). These observations suggest that the deficit in hematopoietic support, in our model,
may be the result of changes in a soluble factor acting in either an autocrine or paracrine
manner to diminish optimal cell:cell interaction or that an unidentifiable adhesion molecule is
influenced by the treatment we tested. Paracrine effects could be modulated, in part, through
alteration of integrin activity, which would not have been detected in our assay. These
observations also suggest very specific effects of chemotherapy on stromal and osteoblast
components of the niche, emphasizing the need to understand each population individually to
understand the total response of the niche to therapy.
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We examined the effect of chemotherapy on osteoblast derived CXCL12. Data in
Figure 3 shows that both chemotherapy and rTGF-β decrease CXCL12 mRNA and protein in
osteoblasts 43. The decrease in CXCL12 correlated with a decrease in chemotaxis of CXCR4+
JM-1 cells towards osteoblasts pre-treated with either melphalan or rTGF-β. However, in
contrast to previous experiments in which we reported chemotactic deficits in VP-16 treated
BMSC 16, no significant reduction in chemotactic support of CXCR4+ JM-1 cells was noted in
the VP-16 treated HOB groups. These data suggest potential drug specific effects in which
melphalan may target CXCL12 expression as well as other critical chemotactic factors in HOB,
while VP-16 does not as globally affect chemotaxis regulators, allowing some maintenance of
chemotactic support. One such factor for future investigation would include stem cell factor
(SCF), which has been shown to synergize with CXCL12 in homing of stem cells and retention
in their developmental niche 44.
Collectively, these data suggest that generation of active TGF-β in the endosteal niche
can negatively affect production of CXCL12, thus impairing progenitor cells from homing to the
bone marrow, engrafting, and reconstituting the patient’s immune system. This observation of
vulnerability of gene expression to genotoxic stress in HOB prompted us to investigate the
magnitude of direct and indirect chemotherapy-induced damage to osteoblasts by microarray
analysis. After 6 hours of treatment, the diverse changes observed in HOB gene expression
alone allow for a better understanding of the significance of the potential damage to the niche
and the subsequent impact on hematopoietic reconstitution that relies on balanced expression
of several proteins. Interestingly, all 3 HOB treatments (rTGF-β, melphalan and conditioned
media from melphalan pre-treated BMSC) evaluated in the microarray analysis identified NF-κB
as a point of convergence (Figure 4). As with all gene expression pathway analysis, in the
absence of targeted genetic manipulation or biochemical analysis, the interactions remain
hypothetical. The most pronounced value of these data in the current study is to provide a
sense of the responsiveness of osteoblasts to genotoxic stress, as well as to factors such as
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TGF-β, which may participate in both autocrine and paracrine signaling in the stem cell niche.
Points of convergence, such as NF-κB, may then provide the focus for a more mechanistic
investigation of cell signaling downstream of stress in the bone marrow microenvironment.
Central to our investigation was an interest in the influence of active TGF-β released
from chemotherapy treated HOB as well as TGF-β that may be released from neighboring
BMSC in a damaged microenvironment as just two potential sources of this growth factor.
Studies by Batard et al have described the importance of low levels of TGF-β in the bone
marrow microenvironment for maintenance of the stem cell pool through up-regulation of the
CD34 antigen, a marker of primitive HSC 38. Consistent with the need for rigorous control of
total TGF-β levels, a number of studies have shown the benefit of TGF-β neutralization during
therapy 45. Lagneaux et al showed that stromal cells isolated from B-CLL patients had
increased TGF-β production correlated with decreased colony-stimulating activity which was
corrected by neutralizing TGF-β activity 13. Using a murine model of breast cancer, Biswas et
al showed that radiation or doxorubicin treatment increased levels of TGF-β which correlated
with increased circulating tumor cells and increased metastasis 46. These effects were
abrogated by anti-TGF-β antibodies providing rationale for utilization of TGF-β inhibitors, such
as GC1008 in clinical trials in the setting of renal cell carcinoma and malignant melanoma 47.
Based on our observations, application of TGF-β neutralizing antibodies may have utility
through influence on both hematopoietic cells and the niche in which they develop.
Our observations indicate that osteoblasts are susceptible to genotoxic stress
documented by alteration of gene expression profiles (Figure 4, S1-4) and functional deficits in
hematopoietic cell support, including differentiation (Figure 2C). Further investigation will identify
targets that may prove useful in augmenting hematopoietic recovery through “balancing” the
stem cell niche following therapy-induced damage. Long-term hematopoietic deficits may, in
fact, derive in part from the immediate changes in the niche that are imposed by aggressive
therapeutic regimens. This aspect of marrow function may highlight an area in which better
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understanding could identify new therapeutic strategies to augment efficient patient recovery
follow bone marrow transplantation.
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Figure legends:
Figure 1: Direct and indirect damage increase HOB levels of active TGF- β. A) HOB were
treated with 50 μg/ml melphalan or 50 μM VP-16 for 24 hours and real time PCR completed (top) and
HOB were treated directly for 4 hours with chemotherapy (100 μM VP-16 or 100 μg/ml melphalan),
fixed and stained for detection of phospho-Smad2 (green), as a read-out of TGF-β activity (bottom)
(DAPI stain for nuclei-blue). B) HOB were treated with 10 ng/ml rTGF-β for 24 hours and real time
PCR completed (left). Additionally, HOB were treated with 10 ng/ml rTGF-β for 24 hours, the HOB
layer was rinsed and new media was added and allowed to condition for 24 hours before being
evaluated by ELISA to quantitate the amount of secreted TGF-β (right).

Figure 2: Chemotherapy or rTGF-β exposure diminished the ability of HOB to support
human embryonic stem cells and CD34+ bone marrow cells and treatment diminishes HOB
interaction with pro-B cells. HOB were pre-treated with 10 ng/ml rTGF-β, 50 μg/ml melphalan or 50
μM VP-16 for 24 hours. HOB were rinsed thoroughly and embryonic stem cells were co-cultured in
complete media as recommended by WiCell. After 2 days of co-culture, stem cell colonies were
counted, stained for Oct-4 as an indicator of potential for pluripotency (A) and designated as
undifferentiated or differentiated based on classic morphology of well defined borders (B). To evaluate
osteoblast support of CD34+ bone marrow cells, HOB cells were treated for 24 hours with 10 ng/ml
rTGF-β, or with 25 μg/ml melphalan. After the 24 hour treatment, the HOB were thoroughly rinsed and
8.8x10^5 CD34+ cells were added in co-culture. Recombinant IL-3 (100 ng/ml) was added in all
groups. CD34+ cells were collected at 2 and 6 days after co-culture and samples were given to
pathology for analysis. Cellular populations were determined by the presence of surface markers (C).
To determine if treatment of HOB affected pro-B cell adherence, HOB were treated with 10 ng/ml rTGFβ, 50 μg/ml Melphalan or 50 μM VP-16 for 24 hours. Adherent layers of HOB were rinsed thoroughly
and co-cultured with 1x105 fluorescently labeled pro-B cells. After 24 hours the media was aspirated
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and non-adherent pro-B cells were gently rinsed. Remaining HOB and pro-B cells adherent to the HOB
layer were then trypsinized and events within the easily distinguishable lymphoid gate, based on
fluorescence and forward/side scatter, were counted on high flow rate for 30 seconds to enumerate
number of pro-B cells attached to the HOB (D).

Figure 3: Chemotherapy or rTGF-β diminishes HOB expression of CXCL12 and support of
pro-B cell chemotaxis. A) HOB were treated with 10 ng/ml rTGF-β, 50 μg/ml melphalan or 50
μM VP-16 for 24 hours. RNA was isolated and real time RT-PCR was performed for CXCL12.
B) HOB were treated with 10 ng/ml rTGF-β, 50 μg/ml melphalan or 50 μM VP-16 for 24 hours.
Growth factor or chemotherapy was removed and fresh media was added, allowed to condition
for 24 or 48 hours, and then evaluated in a CXCL12 specific ELISA. C) HOB were treated with
rTGF-β, 50 μg/ml melphalan or 50μM VP-16 for 24 hours. 350 μl of the supernatant was then
removed and placed into the bottom chamber of a transwell. 1x105 JM-1 progenitor cells were
placed in the top chamber and allowed to migrate for 4 hours. After 4 hours the cells migrated
were read on high flow rate for 30 seconds on a flow cytometer.

Figure 4: Intersection of global gene changes during direct and indirect chemotherapy.

HOB

cells were treated for 6 hours with 10ng/ml rTGF-β, 50 μg/ml melphalan, or conditioned media from
BMSC (CMM) pre-treated with 50 μg/ml melphalan for 24 hours. BMSC exposed to melphalan were
rinsed and fresh media was place on adherent layers to condition and to remove drug prior to
stimulating HOB. After the 6 hour treatment, HOB RNA was isolated and microarray analysis was
completed to evaluate global changes in gene expression. A) The Venn diagram summarizes the
number of HOB genes that changed within each group as well as the changes between the groups. B)
A gene summary was made of the genes that commonly were up-regulated (4, red) or down-regulated
(2, green) for the intersection of all 3 treatments (rTGF-β:CMM:melphalan). C) A network diagram was
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generated for the intersection of all 3 treatment groups that highlights the convergence of potential
pathways associated with those genes such as NF-κB. All genes listed were generated using a 2.5%
FDR and 1.5 fold significant cut off.
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Figure 1: Direct and indirect damage increase HOB
levels of active TGF- β.

60

C.

Oct-4

TGF-β

Cell Population (%)

Melphalan

VP-16

Untreated

Brightfield

Total Cell Population (%)

A.

50
40

40.0

30
18.2

20

6.1

0

4

Erythroid

2.2

50
40
30

*
*

2.4

2.2 2.3

1

0.5
0

Total
Lymphocytes

B-cells

*

20
10

0.1

NK-cells

Cell Type

Number of Adherent pro-B Cells

Percent Undifferentiated Colonies

60

No Treatment
TGF-β
Melphalan

7000

Control
Melphalan
VP-16
TGF-β

70

Cell Type

3.1

3
2

0.6
Granulocytes

3.7

D.
80

18.4

15.5

10

0

B.

No Treatment
TGF-β
Melphalan

Control
Melphalan
VP-16
TGF-β

6000
5000
4000
3000
2000
1000

*
*

*

0

0

Figure 2: Chemotherapy or rTGF-β exposure diminished the ability of HOB to support human
embryonic stem cells and CD34+ bone marrow cells and treatment diminishes
HOB interaction with pro-B cells.
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Abstract
Background: The host’s response to infection is characterized by altered levels of
neurotrophins and an influx of inflammatory cells to sites of injured tissue. Progenitor cells that
give rise to the differentiated cellular mediators of inflammation are derived from bone marrow
progenitor cells where their development is regulated, in part, by cues from bone marrow
stromal cells (BMSC). As such, alteration of BMSC function in response to elevated systemic
mediators has the potential to alter their function in biologically relevant ways, including
downstream alteration of cytokine production that influences hematopoietic development.
Methodology/Principle:

In the current study we investigated BMSC neurotrophin receptor

expression by flow cytometric analysis to determine differences in expression as well as
potential to respond to NGF or BDNF.

Intracellular signaling subsequent to neurotrophin

stimulation of BMSC was analyzed by western blot, microarray analysis, confocal microscopy
and real-time PCR. Analysis of BMSC Interleukin-6 (IL-6) expression was completed using
ELISA and real-time PCR.
Conclusion: BMSC established from different individuals had distinct expression profiles of the
neurotrophin receptors, TrkA, TrkB, TrkC, and p75NTR.

These receptors were functional,

demonstrated by an increase in Akt-phosphorylation following BMSC exposure to recombinant
NGF or BDNF. Neurotrophin stimulation of BMSC resulted in increased IL-6 gene and protein
expression which required activation of ERK and p38 MAPK signaling, but was not mediated by
the NFκB pathway. BMSC response to neurotrophins, including the up-regulation of IL-6, may
alter their support of hematopoiesis and regulate the availability of inflammatory cells for
migration to sites of injury or infection. As such, these studies are relevant to the growing
appreciation of the interplay between neurotropic mediators and the regulation of
hematopoiesis.
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Introduction
Neurotrophins are a family of proteins which are best characterized by their modulation
of survival, differentiation and apoptosis of cells in the nervous system. This family includes
NGF, BDNF, neurotrophin 3 (NT-3), and neurotrophins 4/5 (NT-4/5)1. Neurotrophins signal
through the high-affinity tyrosine kinase (Trk) receptors, TrkA, TrkB, TrkC, and the low-affinity
receptor, p75NTR, a member of the tumor necrosis factor receptor family1;2.
NGF is a survival factor essential for a large number of neuronal and non-neuronal cell
types. The importance of neurotrophin signaling is highlighted by neurodegenerative conditions
such as Alzheimer’s disease, in which there is a dysregulation of pathways modulated by
neurotrophic factors3;4. In addition to its role in neurological pathways, neurotrophin signaling
has an impact on innate and adaptive immunity5. Alteration of NGF has been documented in
autoimmune inflammatory diseases including multiple sclerosis6, psoriasis7, systemic lupus
erythematosus8 and rheumatoid arthritis9. Traumatic brain injury10, neuroectodermal tumors11
and endocrine disorders12 are a few examples of many conditions also associated with
increased neurotrophins. A positive correlation between NGF level and allergic asthma, airway
hyperactivity, total IgE and the number of eosinophils in the serum has also been noted13.
These observations suggest that neurotrophins may mediate hematopoietic responses to
several clinically relevant conditions. Importantly, NGF has the potential to act systemically on
distant organs, including the bone marrow which serves as the primary site of postnatal
hematopoiesis14;15.
BMSC provide the structural and physiological support for hematopoietic cell survival,
proliferation and differentiation. Resident stem and immature hematopoietic progenitor cells
mature under the influence of the bone marrow microenvironment to functional, mature cells of
diverse lineages14;15. As such, exposure of this microenvironment to circulating neurotrophins,
cytokines and growth factors has the potential to alter its function, resulting in the generation of
hematopoietic populations that are markedly different than those in healthy individuals.
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In the current study, a cytokine that was consistently and significantly increased in
BMSC exposed to NGF or BDNF was Interleukin-6 (IL-6). IL-6 is a multifunctional cytokine16
modulated by other factors including IL-1, TNF-α, growth factors, hormones, and viral or
microbial products17-19. Dysregulation of IL-6 production has been reported in the pathogenesis
of several autoimmune diseases including rheumatoid arthritis (RA), systemic-onset juvenile
chronic arthritis (JCA), autoimmune encephalomyelitis, psoriasis, antigen-induced arthritis (AIA),
and Systemic Lupus Erythematosus16;20-22. IL-6 is a critical factor for hematopoiesis through
regulation of the entry of hematopoietic stem cells into the cell cycle, proliferation of cells
committed to the myeloid and lymphoid lineage, and maturation of B-cells into antibody
producing cells16;23-26.

Increased IL-6 expression in transgenic mice results in massive

polyclonal plasmacytosis and malignant plasmacytoma26. In contrast, a reduction in
hematopoietic progenitor cell support has been reported by IL-6 deficient bone marrow stromal
cells27.

These observations suggest that changes in IL-6 levels could impact on the

development of hematopoietic populations available to participate in inflammatory responses
with the novelty of our current study derived from consideration of the potential of systemic
neurotrophic factors to modulate IL-6 in the marrow microenvironment through direct stimulation
of BMSC.
Depending upon the cellular context, IL-6 transcription has been documented to be
influenced by both NF-κB and MAPK (mitogen-activated protein kinase) cascades subsequent
to

NGF

stimulation28;29.

Studies

have

shown

that

NGF

activates

NF-κB

in

rat

pheochromocytoma PC12 cells30. NF-κB is sequestered in the cytoplasm by the IκB family of
proteins which become phosphorylated, and degraded by the proteasome with subsequent NFκB translocation to the nucleus31.

As a transcription factor involved in the control of

inflammatory responses, cellular growth, and apoptosis31, NF-κB is involved in the pathology of
several diseases, including cancers, arthritis, chronic inflammatory bowel disesse, asthma and
neurodegenerative diseases32-36.

Neurotrophin stimulation of the MAPK pathway has been
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documented in the PC12 cell line37, dorsal root ganglia, and transient receptor potential vanilloid
1 (TRPV1) (the capsaicin receptor) model38. Activation of the TrkA receptor by NGF in airway
smooth muscle cells also leads to activation of the MAPK cascade including p38 MAPK, and
extracellular-regulated protein kinase 1/2 (ERK1/2)39. Following stimulation, the MAPK family of
proteins activate several downstream factors involved in regulating inflammation37-39.
Based on the diverse set of pathologic conditions associated with dysregulated
neurotrophic factors, many of which involve inflammation as a central feature, we investigated
the effects of NGF and BDNF on BMSC function as a critical influence on regulation of
hematopoietic cell development.

Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed in the Declaration of
Helsinki. The study was approved by the Institutional Review Board of West Virginia University.
All patients provided written informed consent for the collection of samples and subsequent
analysis.

Cell culture and reagents
P163, P164, PED299, PED604, PED62304 and GPBM 1-32 primary human bone
marrow stromal cells (BMSC) were derived from consenting donors (written consent) with the
approval of the West Virginia University Institutional Review Board. Establishment of BMSC
and their characterization have been previously described in detail40. Because the
characteristics of BMSC can be influenced by preparative regimens, all lines were established
identically and evaluated at comparable passage number in the experiments presented. BMSC
were maintained in Minimum Essential Medium, Alpha (α-MEM) (Mediatech, Manassa, VA)
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supplemented with 10% fetal bovine serum (FBS) (Hyclone, Pittsburgh, PA), 2mM L-glutamine
(Mediatech) 100 mg/ml streptomycin, 100 IU/ml penicillin (Sigma, St. Louis, MO), and 5x10-5M
2-β mercapthanol (Sigma), at 37˚C in 6% CO2. Of note, the concentration of 2- β mercapthanol
used is less than that published as having the potential to stimulate cells to neural
differentiation41. The adherent, fibroblastic BMSC utilized in all of our studies constitutively
express VCAM-1, Fibronectin, SDF-1 (CXCL-12), VEGF, Thrombospondin and a variety of
cytokines that influence both lymphoid and myeloid cell survival and expansion.

Flow cytometric analysis
Six different BMSC lines were grown to confluence (~106 cells), trypsinized, fixed in 10%
formaldehyde for 30 minutes, and subsequently permeabilized in 70% EtOH for 30 minutes on
ice. To reduce non-specific antibody binding, BMSC were blocked in 3% BSA in PBS for 15
minutes and subsequently incubated with 1μg per sample of rabbit polyclonal TrkA or TrKB,
goat polyclonal p75NTR specific antibodies from Santa Cruz Biotechnology,Inc. (Santa Cruz,
CA). For detection of TrkC, TrkC-PE (FAB373P) and isotype control goat IgG-PE were acquired
from R&D systems (Minneapolis, MN). The additional isotype control antibody, rabbit IgG, was
purchased from Southern Biotechnology (Birmingham, AL).

Primary antibody binding was

detected by incubation with 1μg per sample fluorescein isothiocyanate (FITC)–conjugated goat
anti-rabbit (Santa Cruz Biotechnology) for Trk A and TrkB and FITC–conjugated rabbit anti-goat
IgG(H+L) (Southern Biotechnology) for p75NTR. Data were acquired by counting 10000 events
and analyzed using FACSCalibur (BD Biosciences, San Jose, CA). One representative cell line
from the six lines examined was chosen for completion of the remaining experiments in the
manuscript unless indicated.

69

Western blot analysis
Confluent BMSC were treated with 100 ng/ml mouse NGF 2.5 S (Roche Applied
Science) or recombinant human BDNF (Invitrogen, Carlsbad, CA) for 5 minutes, 30 minutes, 1
hour and 6 hours. Following treatment, BMSC were lysed in complete cell lysis buffer (50 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 1% Triton X-100, 0.25% Na-deoxycholate, 1 mM EDTA, and 1
mM NaF, 1 mM DTT, 1 mM PMSF, 1 mM activated Na3VO4, 1 μg/mL aprotinin, 1 μg/mL
leupeptin, and 1 μg/mL pepstatin) on ice for 15 minutes. Following centrifugation at 20,000x g
for 15 minutes, supernatants were collected and protein concentration was determined using
the bicinchoninic acid protein assay (BCA).

Proteins were resolved on SDS-PAGE and

transferred to nitrocellulose membranes (Schleicher & Schuell Bioscience, Keene, New
Hampshire). Membranes were blocked in TBS/5% nonfat dry milk/0.1% Tween-20 at room
temperature for 1 hour, and probed with the primary antibodies rabbit anti-phospho-Akt (Ser473)
or rabbit anti-Akt, (Cell Signaling Technology, Inc, Danvers, MA). Additional antibodies included
rabbit Erk 1/2 (Cell Signaling Technologies) and anti-phospho ERK1/2 purchased from Promega
Corporation (Madison, WI). Mouse anti-GAPDH (Fitzgerald Industries International, Concord,
MA) was used as a lane loading control.

Washes were in TBS/0.1% Tween-20 following

incubation with horseradish peroxidase-conjugated secondary antibodies. Luminol (Santa Cruz
Biotechnology) generated signal was detected on x-ray film.

Densitometric analysis was

performed using the Fotodyne imaging system with Foto/Analyst version 5.00 software
(FOTODYNE Inc., Hartland, WI) for image acquisition, and TotalLab version 2005 software for
analysis.

Cellular Fractionation and Western Blot Analysis
BMSC were left untreated or treated with NGF (100ng/ml) for 30 min. Cells were
trypsinized, pelleted and cellular fractionation was completed using the NE-PER cytoplasmic
and nuclear extraction kit (Pierce Biotechnology, Rockford, IL). Protein concentration was
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determined using the bicinchoninic acid (BCA) protein assay (Pierce Biotechnology).
Cytoplasmic and nuclear proteins were resolved on SDS-PAGE gels and transferred to
nitrocellulose membranes. Membranes were blocked with 5% nonfat dry milk/ 1X TBS/0.1%
Tween-20 and probed with a mouse monoclonal p65 specific antibody. After incubation with
anti-mouse HRP- conjugated secondary antibody, the signal was visualized using Immobilon
chemiluminescence reagents (Millipore, Billerica, MA).

RNA Isolation
Total RNA was isolated from three BMSC lines treated with NGF or BDNF (100ng/ml)
using the Qiagen RNeasy Mini kit following the recommendations of the manufacturer (Qiagen,
Valencia, CA). Pelleted BMSC were lysed by centrifugation through QIA shredder spin columns
and RNA was treated with 1U DNAse for 15 minutes at 24°C. Samples were quantified at
260nm (GENESYS-10UV, Spectronic, Unicom) and protein contamination determined by
evaluation at 280 nm.

Microarray analysis
Gene expression profiles of BMSC were assessed using the Human Neurotrophin and
Receptor Gene Array HS-018 (SuperArray, Frederick, MD) as a representative, but not
exhaustive, approach for screening of NGF or BDNF induced changes in gene expression.
BMSC RNA from untreated control and NGF or BDNF treated cells was converted to
biotinylated cDNA using the Ampolabeling-LPR kit (SuperArray). Membranes were hybridized
with cDNA probes overnight at 60°C with continuous agitation at 5–10 r.p.m and then washed
as recommended by the manufacturer. Signal was detected on X-ray film with images scanned
and analyzed with GEArray Expression analysis suite software (SuperArray). Signal intensities
were normalized to GAPDH and beta-actin on each membrane. Only those genes having a 3
fold or higher change in expression were examined (GEO accession number GSE18537).
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Real-time PCR
To determine relative IL-6 expression, real-time PCR was used to validate data from
microarray experiments. The one-step QuantiTect SYBR Green RT-PCR Kit (Qiagen) was
used as recommended by the manufacturer. All reactions were performed in triplicate using 80
ng of RNA per reaction, IL-6 gene primers (#PPH08958A; SuperArray) or the housekeeping
gene GUSB (beta glucuronidase) (Real Time Primers, Elkins Park, PA). Amplifications were
completed using a 7500 real-time PCR system (Applied Biosystems, Foster City, CA).
Amplification conditions included 50°C for 30 minutes, 95°C for 15 min, 45 cycles of 94°C for 15
seconds, 55°C for 30 seconds, and 72°C for 45 seconds. The relative quantitative method
(DDCT) was used to evaluate gene expression in experimental and control cells for each gene
examined42.

ELISA
BMSC were cultured in a 96-well plate and serum deprived (1% FBS) for 24h before
treatment with 100 ng/ml NGF or BDNF for 24 or 48 hours. Supernatants were collected and a
human IL-6 ELISA completed (eBioscience, San Diego, CA) with 1/20 dilution of supernatants
as recommended by the manufacturer. For experiments in which the effects of MEK and MAPK
inhibition were studied, 20µM of the MEK inhibitor U0126 or 10µM of the p38 MAPK inhibitor SB
203580 (Promega) were added 2 hours before treatment with NGF or BDNF in select wells.
Integrity of cell layers were confirmed prior to collection of supernatants.

Immunostaining and confocal microscopy
BMSC were grown to confluence on glass coverslips and treated with 100 ng/ml NGF,
BDNF or rTNF-α (R&D Systems), for 5, 30 and 60 minutes. Following treatment, BMSC were
rinsed in phosphate-buffered saline (PBS) and fixed in 4% formaldehyde at room temperature
for 30 minutes, followed by rinsing and fixing in acetone for 10 minutes. Permeabilization of
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cells was completed with 0.5% Triton X-100 for 30 minutes. Nonspecific antibody binding was
blocked by incubation of BMSC for 30 minutes in PBS/5% BSA.

NF-κB localization was

evaluated by incubation of BMSC with 2 μg/coverslip of mouse anti-human monoclonal NF-κB
p65 (Santa Cruz Biotechnology) in PBS/5% BSA for 1 hour. Subsequently, Alexa Fluor 555
donkey anti-mouse IgG(H+L) (Invitrogen), was applied at a 1 μg/coverslip for one hour.
Coverslips were then inverted on slides and mounted with Prolong Gold antifade reagent with 4,
6 diamidino-2-phenylindole (DAPI) (Invitrogen). Images were collected using a Zeiss LSM510
confocal on an AxioImager Z1 microscope (Carl Zeiss) with a 405-diode laser to excite DAPI
and a 543 HeNe laser to excite the AlexaFluor 555-labeled secondary antibody. Cells were
visualized using a 40x/1.30 oil objective. All confocal images were adjusted equally using Adobe
Photoshop.

Statistical analysis
Data presented were expressed as mean ± SEM for triplicate samples. Statistical
analysis was performed by ANOVA (p 0.01 determined as significant) and Student t-test (p
0.01 determined as significant).

Results
BMSC have distinct expression profiles for TrkA, TrkB, TrkC and p75NTR.
To determine the expression pattern of neurotrophin receptors by BMSC, flow cytometry
analysis of BMSC with antibodies specific for, TrkA, TrkB, TrkC and p75NTR was performed.
While the levels of expression for a given receptor varied between stromal lines derived from
different individuals, all BMSC lines used in this study expressed both the high and low affinity
receptors to respond to neurotrophins (Figure 1).
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BMSC demonstrate Akt phosphorylation following NGF or BDNF exposure.
Activation of Akt occurs in response to a variety of stimuli, and relevant to the current
study, is a well documented consequence of neurotrophin stimulation43. Therefore, while not a
investigative focus in this work, the phosphorylation of Akt was utilized simply as a read-out to
determine if BMSC could respond to neurotrophin binding to the Trk receptors. Phosphorylation
of Akt occurred rapidly following BMSC exposure to 100 ng/ml of NGF or BDNF. NGF treated
BMSC Akt phosphorylation was detected as early as 5 minutes with the peak signal occurring at
30 minutes. Phosphorylated Akt began to diminish by 1 hour, and minimal signal was detected
after 6 hours of exposure to NGF. In BDNF treated cells, peak phosphorylation of Akt occurred
at 5 minutes and gradually diminished over 6 hours (Figure 2).

Exposure to NGF or BDNF increases IL-6 gene expression in the BMSC.
To investigate the cytokine pattern of BMSC exposed to neurotrophic factors, RNA
isolated from BMSC exposed to NGF and BDNF was analyzed by microarray as described.
While many genes were increased, and fewer decreased, following NGF or BDNF exposure,
with a cut-off of 3 fold-change compared to untreated controls, Fibroblast Growth Factor-2
(FGF2) and IL-6 emerged as those genes markedly upregulated following NGF or BDNF
treatment in this panel (Figure 3 A-B). In addition, the BDNF receptor (NTRK2) and CRH1 gene
expression increased following NGF exposure, but did not meet the threshold cutoff in cells
exposed to BDNF. IL-6 was chosen for further investigation to determine the signaling pathway
that may underlie altered expression based on its well characterized role in hematopoiesis.
To validate our IL-6 microarray data, relative transcript levels were determined by
quantitative real-time PCR. Consistent with the microarray data, IL-6 mRNA increased in BMSC
after exposure to both NGF and BDNF (Figure 3 C-D).
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BMSC exposed to NGF or BDNF demonstrate increases in IL-6 protein consistent with
gene expression changes
To evaluate effects of NGF or BDNF on IL-6 protein, BMSC were serum deprived (1%
FBS) for 24 hours and subsequently exposed to 100 ng/ml of NGF or BDNF for 24 or 48 hours
in triplicate. An IL-6 ELISA was performed on the supernatant collected from each time point to
determine changes in the production of IL-6 protein. Consistent with the up-regulation of IL-6
message, exposure of BMSC to NGF and BDNF increased the level of IL-6 protein (Figure 4).
To determine the optimal concentration of neurotrophins needed to induce NGF or BDNF
signaling, resulting in IL-6 protein increase, a dose response curve was completed, using an IL6 ELISA with doses of neurotrophins ranging from 0-100 ng/ml. A MTT assay was used to
determine the concentrations of neurotrophins used were not toxic to the BMSCs (data not
shown). To determine if there is a role for the sIL-6R in our model, BMSC were left untreated or
stimulated with NGF or BDNF (10-100ng/ml) for 24 hours and a sIL-6R ELISA was completed.
There was no detectable sIL-6R present in the untreated cells or in those cells treated with NGF
or BDNF (data not shown).

Neurotrophins do not induce NF-κB signaling in BMSC
In neurons, it has been established that neurotrophin stimulation activates signaling through NFκB30. Additionally, NF-κB is a known transcription factor for IL-628.

Using

immunofluorescence, we determined whether exposure of BMSC to neurotrophins induced
nuclear translocation of the p65 subunit of NF-κB. BMSC (one cell line) were exposed to either
NGF or BDNF. Subsequent to NGF or BDNF exposure, no nuclear translocation of the NF-κB
p65 subunit was noted. In contrast, rTNF-α, which was used as a positive control, induced rapid
translocation of the p65 subunit from the cytoplasm to the nucleus in the BMSC (Figure 5A). To
confirm the lack of p65 translocation to the nucleus with NGF stimulation, BMSC were left
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untreated or treated with NGF (100ng/ml) for 30 min. Following treatment, cellular fractionation
was completed and the fractions analyzed by western blot with p65 specific antibodies. There
was no detectable p65 in the nuclear fraction of untreated or NGF treated cells, while p65 was
readily detected in the cytoplasmic fraction (Figure 5B). GAPDH was used as a fraction
contamination control (data not shown).

NGF and BDNF induce MAPK ERK1/2 signaling pathway
Stimulation of neuronal TrkA with NGF has been shown to activate the MAPK components
ERK1/2 and p38 MAPK39. To evaluate the role of neurotrophin induced MAPK signaling in
BMSC, we analyzed phosphorylation of ERK1/2 as a read out of MAPK activation following
BMSC exposure to NGF or BDNF. Phosphorylation of ERK occurred rapidly and transiently in
both NGF and BDNF treated groups while no phosphorylation was detected in untreated control
cells (Figure 6).

MAPK ERK1/2 pathway inhibitors blunted IL-6 production following NGF or BDNF
exposure.
As shown previously (Figure 4), treatment with NGF or BDNF increased IL-6 protein in BMSC
supernatants. The increase in IL-6 protein with NGF or BDNF stimulation without any inhibitors
was statistically significant (p=.001 for NGF and p=.002 for BDNF) (Figure 7).

To further

investigate the role of ERK1/2 and p38 pathway in neurotrophin induction of IL-6, specific
inhibitors targeting both pathways were utilized as discussed in methods. Pre-treatment of
BMSC with U0126 and SB 203580 in concentrations held low enough to maintain specificity of
inhibition resulted in approximately a 50% decrease of IL-6 upon exposure to NGF or BDNF
(Figure 7). To investigate the role of the Akt pathway in neurotrophin induction of IL-6, BMSC
were pre-treated as described above with Akt VIII, a specific Akt inhibitor, for 2 hrs prior to
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stimulation with NGF or BDNF. Akt inhibition did not decrease IL-6 protein detected in BMSC
supernatants (data not shown).
Discussion
The purpose of this study was to determine if BMSC gene expression is responsive to
NGF or BDNF as a means by which neurotrophic factors may indirectly influence
hematopoiesis. Many in vivo and in vitro studies have investigated the role of neurotrophins in
hematopoiesis. NGF has been demonstrated as an important factor for hematopoietic colony
growth and differentiation44.

Previous work documents its ability to directly influence

proliferation, differentiation, and maturation of myeloid progenitors along with induction of
migration, survival and activation of mature hematopoietic cells45-47. NGF is also a chemotactic
stimulus for human leukocytes and macrophages48;49. Fewer studies have focused specifically
on the response of BMSC to neurotrophic factors as the mechanism by which NGF or BDNF
may indirectly influence hematopoiesis.

However, there have been previous reports that

document the expression of NGF receptors on BMSC50 as well as the capacity of BMSC to
produce and respond to NGF during normal hematopoiesis51. The role of BDNF on immune
function and hematopoietic cell development is not as well defined as NGF, although impaired B
cell development in bone marrow of BDNF deficient mice has been reported52.
We have demonstrated expression of both high and low affinity receptors for
neurotrophins by BMSC, with their level of expression varying between BMSC donors (Figure 1
A-D). While in some settings signaling through the low affinity receptor p75 following NGF
exposure can result in apoptosis53, in the presence of TrkA the signals are predominantly
reported to be anti-apoptotic54. Co-expression of both high and low affinity receptors by human
BMSC appear to have favored the anti-apoptotic effects of neurotrophin signaling.

The

neurotrophin receptors are functional as demonstrated by Akt-phosphorylation following
stimulation of BMSC by NGF and BDNF (Figure 2 A-B). Phosphorylation of Akt, while it may
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influence survival of BMSC consistent with its role in several settings, was not being
investigated in its survival context in our model. Rather, as a well characterized downstream
target of neurotrophic signaling it was merely monitored as a measure of functionality of
receptors in the absence of a clearly defined signal more immediately stimulated by NGF or
BDNF in BMSC.
Through microarray analysis we demonstrated that cytokine gene expression by BMSC
changes in response to NGF or BDNF exposure (Figure 3 A, B). Any focused panel of gene
expression analysis is, by design, not an exhaustive evaluation of all the potential targets that
respond to any stimulus. As such, we chose a focused evaluation, and subsequently targeted
IL-6 for follow up based on its diverse involvement in innate immunity, hematopoiesis, and
inflammatory responses16.

Consistent with the microarray data, IL-6 gene and protein

expression increased after exposure to both NGF and BDNF as determined by real-time PCR
and ELISA respectively (Figure 3 C, D and Figure 4).

In addition to IL-6, FGF2 was

increased more than three-fold that of matched controls by both BDNF and NGF. Previous
reports have indicated that elevated FGF2 decreased both stromal cell derived factor-1 (SDF1;CXCL12) mRNA and protein in vivo and also diminished the capacity of BMSC to support the
expansion of peripheral blood derived stem cells55.

Uniquely, the Trk B receptor (NTRK2) was

increased by NGF, but not BDNF, with the increase reaching our threshold cut-off of three times
that of untreated cells. This increase suggests a potential synergistic relationship between
these two neurotrophic factors in which an NGF increase may position BMSC cells to more
robustly respond to BDNF through modulation of TrkB receptor expression. Consequently,
subtle increases in circulating BDNF may have pronounced signaling potential when NGF
increases have occurred previously.
The significant role of IL-6 in inflammation has been demonstrated by the diminished
ability of IL-6 knockout mice to respond to environmental air pollutants exposure compared to
wild-type control56. Of specific relevance to the current study, IL-6 overproduction in transgenic
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animals resulted in an increase in the number of megakaryocytes, plasmacytosis formation and
extramedullary hematopoiesis26;57, suggesting elevated IL-6 subsequent to circulating NGF or
BDNF may contribute to dysregulated immune function. Of note, all reports are not consistent
with a clear inflammatory response subsequent to increased NGF, with a recent study
suggesting that NGF may, in fact, have anti-inflammatory actions via its regulation of calcitonin
gene-related peptide (CGRP) in monocytes58.

This recent work highlights the necessity of

interpreting data within the confines of the specific model being investigated.
Our data do not rule out the possibility of NGF or BDNF acting on gene expression in
BMSC through one, or several, intermediate factors.

Increased expression or release of

Substance-P following neurotrophic stimulation of cells has been described in diverse settings
documenting its important role in the hematopoietic-neuro-immune axis in inflammation, as well
as normal and malignant hematopoiesis59-64. Relevant to our model, Substance-P has been
shown to participate in upregulation of inflammatory cytokines in fibroblastic cells65;66 and more
recently in a model of increased IL-6, IL-1β, and TNF-α in a model of burn-induced lung injury67.
These reports raise the possibility that Substance-P may be an intermediate between
neurotrophic factor exposure and altered gene expression in BMSC as well which has not been
investigated. Studies that include targeted knock-out of Substance-P will be intriguing, and are
required to determine if it is a required mediator of signaling in BMSC. However, regardless of
outcome, the biological significance remains that functional changes in a critical component of
the marrow microenvironment, BMSC, can be elicited by circulating NGF or BDNF.
Different

reports

suggest

several

pathways

mediate

IL-6

induction

and

the

immunomodulatory effects of neurotrophins based on the stimulus and cell type. Our study
demonstrated phosphorylation of ERK1/2 MAPK (Figure 6 A, B), with no nuclear translocation of
NF-κB detected (Figure 5) following NGF or BDNF treatment of BMSC.

Furthermore, we

observe that ERK1/2 and p38 MAPK pharmacological inhibitors (U0126 and SB203580)
significantly reduced IL-6 production by BMSC during exposure to NGF or BDNF (Figure 7).
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This observation is consistent with a recently reported model that included LPS stimulated
BMSC in which SB-203580 inhibited IL-6 and IL-11 mRNA expression68. Our data suggest ERK
and p38 MAPK pathways are required for optimal BMSC IL-6 induction by NGF and BDNF, with
these pathways likely involved in baseline expression of IL-6 as a reduction in steady state
expression was noted with both inhibitors in the absence of any neurotrophic stimulation. The
inhibition noted following stimulation was approximately 50% suggesting that other pathways
are also involved in NGF and BDNF stimulated IL-6 production. While a dose response of
increased inhibitor concentration could be completed to determine if more pronounced inhibition
can be achieved, the approach is not valid based on the loss of specificity that will occur at
higher doses.

Therefore, experiments were completed with the concentration limited to

generate meaningful results.
Collectively these data suggest BMSC can be modulated by neurotrophins in a manner
consistent with influence on hematopoietic cell proliferation and differentiation, reflected by a
significant IL-6 increase in this study. As such, neurotrophins are positioned to regulate the
availability of inflammatory cells derived from the marrow, through both direct44-47 and indirect
mechanisms.

Taken together, our data suggest a central role for neurotrophins in the

inflammatory process subsequent to infection and identify bone marrow stroma as a novel
target for these factors. Further, this study broadens the context in which we should consider
the consequences of dysregulated neurotrophin expression.
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Figure Legends
Figure 1.

BMSC express neurotrophin receptors.

BMSC established from different

individuals were stained for high affinity receptors (A) TrkA, (B) TrKB, (C) TrkC and the low
affinity receptor (D) p75NTR with specific antibodies followed by flow cytometric evaluation.
BMSC expressed distinct profiles of neurotrophin receptors.

Isotype matched controls are

indicated by the solid histogram.

Figure 2.

BMSC Akt phosphorylation increases following NGF or BDNF exposure.

Following treatment with NGF or BDNF, BMSC were lysed and protein was resolved by SDSPAGE and transferred to nitrocellulose membranes. (A) Membranes were probed with
antibodies specific for phospho-Akt and total Akt; GAPDH was used as a lane loading control.
(B) Densitometry demonstrates an increase in phospho-Akt:Total Akt following NGF or BDNF
exposure.

Figure 3. NGF or BDNF changes the gene expression profile of BMSC and increases IL-6
mRNA. BMSC were treated with 100 ng/ml of (A) NGF or (B) BDNF for 18 hours. The cells
were collected, RNA was isolated, and microarray analyses were performed. Graphs
summarize the panel of gene expression changes in the BMSC treated with NGF or BDNF
compared to untreated control cells. BMSC were treated with 100ng/ml of (C) NGF or (D)
BDNF for 1, 2, 4 and 8 hours. The cells were collected, RNA was isolated and real time PCR
was performed with the one-step QuantiTech SYBR Green kit as instructed by the
manufacturer. BMSC IL-6 expression in response to NGF or BDNF exposure compared to
untreated control cells is shown. Expression was normalized to the housekeeping gene GUSB.
Statistical analysis was completed by ANOVA (P ≤ 0.0001) with significance indicated by an
asterisk.
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Figure 4. BMSC treatment with NGF or BDNF increases IL-6 protein. BMSC were exposed
to 100 ng/ml of NGF or BDNF for 24 and 48 hours. The supernatant was then collected and an
IL-6 ELISA was performed.

An increase in BMSC IL-6 protein was noted in all treatment

groups. Statistical analysis was completed by ANOVA (P ≤ 0.01) with significance indicated by
an asterisk.
Figure 5. Neurotrophins do not induce NF-κB signaling in BMSC. BMSC were treated with
100 ng/ml of NGF, BDNF, or TNFα for 5, 30 and 60 minutes. Following treatment, BMSC were
fixed and probed with antibodies specific for NFκB p65 or its matched isotype control. Analyses
of samples by confocal microscopy indicate cytoplasmic p65 in untreated control and
translocation of p65 to the nucleus upon stimulation with a known positive stimulus, TNF-α (A).
The subcellular localization of p65 did not change in response to NGF or BDNF.
Representative images from 30 minutes exposure to stimuli are shown (original magnifications
×40). (B) BMSC were left untreated or treated with NGF (100ng/ml) for 30 min. and subcellular
fractionation and western blot analysis completed with p65 specific antibodies. Treatment of
BMSC with NGF did not change the subcellular localization of p65.

Figure 6. BMSC demonstrate activation of MAPK ERK following NGF or BDNF exposure.
Following treatment with100 ng/ml of NGF or BDNF, BMSC were lysed and protein was
resolved by SDS-PAGE and transferred to nitrocellulose membranes. (A) Membranes were
probed with antibodies specific for phospho ERK1/2 and total ERK; GAPDH was used as a lane
loading control. (B) Densitometric quantitation of increase in phosphorylated Erk:Total Erk
following NGF or BDNF exposure.
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Figure 7. ERK and p38MAPK pathway inhibitors blunted IL-6 protein increase during
NGF or BDNF exposure. A MEK1/2 inhibitor, U0126, and p38 MAPK inhibitor SB 203580 was
introduced to BMSC cultures 2 hours prior to NGF or BDNF exposure.

BMSC were then

exposed to 100 ng/ml of either NGF or BDNF for 24 hours and an IL-6 ELISA was performed on
collected supernatants. BMSC pre-treated with U0126 or SB 203580 demonstrated greater
than 50% decrease in IL-6 protein upon exposure to NGF or BDNF. Statistical analysis was
completed by ANOVA (P ≤ 0.01) with significance indicated by an asterisk. Groups that included
inhibitor were compared to matched group with no inhibitors. BMSC treated with NGF or BDNF
without inhibitors had a significant increase in IL-6 protein (p=.001 and p=.002 respectively as
determined by a Student’s t-test).
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Figure 5. Neurotrophins do not induce NF-κB signaling in BMSC.
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Abstract
Bone marrow stromal cells (BMSC) and osteoblasts are critical components of the
microenvironment that support hematopoietic recovery following bone marrow transplantation.
Aggressive chemotherapy not only affects tumor cells, but also influences structural and
functional components of the microenvironment. Successful stem cell or bone marrow
transplantation following myeloablative chemotherapy is dependent on the cellular components
of the microenvironment to maintain their functionality through secretion of soluble factors and
expression of cellular adhesion molecules. In the current study, we investigated the effects of
chemotherapy treatment on BMSC and human osteoblast (HOB) expression of Interleukin-6 (IL6).
IL-6 is a pleiotrophic cytokine which has diverse effects on hematopoietic cell
development. The treatment of BMSC or HOB with melphalan leads to decreases in IL-6
protein expression. The decreased IL-6 protein is the most pronounced with melphalan
treatment compared to several other chemotherapeutic agents tested. We also observed that
melphalan decreased IL-6 mRNA and the addition of rIL-6 in combination with melphalan
treatment restored both IL-6 mRNA and protein. Further investigation is necessary to determine
the exact mechanism by which chemotherapy affects expression of IL-6, likely at a
transcriptional level based on observations of decreased IL-6 mRNA with melphalan treatment.
Collectively, these observations suggest that chemotherapy induced alteration of the bone
marrow microenvironment, focusing on an IL-6 deficit, may result in decreased or defective
hematopoietic support of early progenitor cells. In addition, the decrease in IL-6 protein may be
important for the use of melphalan as a therapeutic agent for multiple myeloma, where IL-6
present in the bone marrow microenvironment is a proliferative factor and leads to disease
progression.
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Introduction
The ability of the supportive cells of the bone marrow microenvironment, including bone
marrow stromal cells (BMSC) and osteoblasts that comprise the endosteal niche, to maintain
their functional integrity following chemotherapy or irradiation is vital for efficient reconstitution of
hematopoiesis. The importance of specialized niches within the marrow environment that
support stem cell self-renewal and a supply of mature blood cells has been described in detail14

.
Several groups have documented chemotherapy-induced stromal cell damage. In

addition, BMSCs isolated from patients receiving standard chemotherapy regimens had a
reduced capacity to form confluent monolayers5. Chemotherapy-induced damage diminishes
the ability of the BMSCs to self-repair, ultimately leading to decreased numbers of functional
mature blood cells6. Galotto et al demonstrated that the patients receiving allogenic bone
marrow transplants have irreversible stromal damage measured using functional assays that
showed CFU-F frequencies did not recover to normal levels even after 12 years posttransplant7. These investigations emphasize the vulnerability of the components of the
endosteal niche.
Interleukin-6 (IL-6) is a pleiotropic cytokine that has important roles in expansion of
hematopoietic progenitors, induction of acute-phase proteins for immune and inflammatory
responses, and regulation of bone metabolism8;9. IL-6 is secreted from BMSCs and
osteoblasts, and has proliferative and anti-proliferative effects. In the bone marrow
microenvironment, IL-6 regulates B-cell differentiation and stimulation of T-cells, both necessary
to maintain the immune system10. An IL-6 deficiency in the microenvironment decreases DNA
synthesis in normal hematopoietic progenitor cells11. Long-term bone marrow cultures
established from IL-6 knockout mice had delayed stromal cell layer development. Additionally,
reduced hematopoietic support activity, measured by CFU-GM, BFU-E, and cobblestone areas,
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which are characteristic of active hematopoietic proliferation was noted in the absence of IL-6 as
well 11. Moreover, IL-6 deficient mice have impaired immune and acute-phase responses12. IL6 deficient mice challenged with diverse viruses and pathogens demonstrated acute-phase
inflammatory responses were compromised12. Relevant to the current study, Patchen et al
observed that IL-6 administration following radiotherapy accelerated multilineage hematopoietic
recovery in a murine model13. Based on the association of IL-6 deficits with sub-optimal
hematopoietic recovery, we undertook investigation to determine whether chemotherapy
dysregulates IL-6 expression in BMSC and osteoblasts as one factor involved in the
dysregulated hematopoietic support capacity of the bone marrow microenvironment following
dose-escalated chemotherapy.
In the current model of chemotherapy-induced damage we included the
chemotherapeutic agents melphalan and VP-16. Melphalan is extensively used in pretransplant chemotherapy regimens for autologous stem cell and allogeneic stem cell
transplantations14;15. As such, damage imposed by chemotherapy on the microenvironment is
of pronounced clinical relevance.
Our results indicated that BMSCs and osteoblasts express diminished IL-6 protein
following chemotherapy treatment with melphalan and to a lesser extent, following VP-16
exposure. We also report chemotherapy-induced reductions of IL-6 mRNA that are not due to
increased instability of mRNA in cells stressed by cytotoxic agents and are not associated with
overt changes in three critical transcription factors. Collectively, our data suggest that
melphalan treatment induces an IL-6 deficit in BMSCs and osteoblasts of the endosteal niche,
potentially contributing to diminished ability of the bone marrow microenvironment to support
reconstitution of hematopoiesis following myeloablative chemotherapy and subsequent bone
marrow or stem cell transplantation. We also observed that recombinant IL-6, in combination
with melphalan treatment, can help to restore IL-6 mRNA and protein levels suggesting that the
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addition of IL-6 is potentially able to restore disrupted IL-6 expression, leading to transcription
and subsequently, translation of IL-6.

Materials and Methods
Cell culture and reagents
Primary human bone marrow stromal cells (BMSC) were derived from consenting
donors with the approval of the West Virginia University Institutional Review Board. The cells
were maintained in alpha-modification of Eagle’s medium (α-MEM) supplemented with 2mM Lglutamine, 10% fetal bovine serum (Hyclone, Logan, UT), 100mg/ml streptomycin, 100 IU/ml
penicillin and 5x10-5M 2-β mercaptoethanol at 37°C in 6% CO2. Primary human osteoblasts
(HOB) were obtained from PromoCell (Heidelberg, Germany) and maintained in complete
osteoblast growth media as recommended by the manufacturer. Phenotype of the osteoblasts
is confirmed by both alkaline phosphatase staining and bone mineralization assays. In
experiments that include chemotherapy treatment, melphalan (Sigma Aldrich, St. Louis, MO)
was used at a concentration of [50 μg/ml]. Melphalan was dissolved in diluent at a
concentration of 2.5 mg/ml immediately before use. Etoposide (VP-16) (Bristol-Myers Squibb,
New York, NY) was stored at a concentration of 33.98 mM and a final concentration of 50 μM
was used in all experiments. Methotrexate (Sigma) was used at [50 ug/ml], vincristine (Sigma)
was used at [20 μg/ml], docetaxel (Sigma) was used at [50 μM] and carboplatin (Sigma) was
used at [50 μM].

ELISA
BMSC and HOB were cultured in a flat bottom 96 well plate in α-MEM complete media
or complete osteoblast growth media until confluent, and subsequently treated with melphalan
[50μg/ml] for 24 hours. Following treatment, the media was replaced, supernatants collected at
2, 4, 6, 8, 24, and 48 hours post-treatment and the confluent layers of BMSC and HOB were
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lysed in RIPA buffer to allow quantitation of both supernatant and intracellular IL-6 protein
levels. Following collection of samples at all timepoints, an IL-6 ELISA (eBioscience, San
Diego, CA) was completed. BMSC and HOB were treated for 24hrs with melphalan [50ug/ml],
VP-16 [50uM], methotrexate, vincristine, docetaxel or carboplatin. Following treatment, the cells
were rinsed, media replaced and supernatants collected at 2, 4, 6, 8, 24 or 48hrs post-treatment
and and IL-6 ELISA completed (eBioscience).

RNA Isolation and Real Time PCR
Total RNA was isolated using the Qiagen RNeasy kit following the recommendations of
the manufacturer (Qiagen Inc., Valencia, CA). RNA concentration was determined by
NanoDrop. To determine relative levels of IL-6 expression, real-time PCR was completed. All
reactions were performed in triplicate using 50 ng of RNA per reaction and the one-step
QuantiTect SYBR Green RT-PCT kit (Applied Biosystems, Foster city, CA). IL-6 gene primers
(Real Time Primers, Elkins Park, PA) or the housekeeping gene beta-glucuronidase (GusB)
(Real Time Primers) were used. Amplifications were completed using a 7500 real-time cycler
(Applied Biosystems). The amplification conditions were 50°C for 30 minutes, 95°C for 15
minutes and 45 cycles of 94°C for 15 seconds, 55°C for 30 seconds, and 72°C for 45 seconds.
The relative changes in gene expression were calculated using the Comparative Ct method16.

Results
Melphalan treatment of BMSCs and HOBs results in diminished IL-6 protein.
To determine if melphalan disrupted IL-6 protein expression, BMSCs and HOBs were
exposed to melphalan [50μg/ml] and an IL-6 ELISA completed using both cell supernatants and
lysates. Melphalan treatment led to decreased IL-6 protein detected in supernatants and
lysates of both BMSCs and HOBs. To determine if IL-6 protein detection was decreased due to
expression of the soluble IL-6 receptor (sIL-6R), BMSCs and HOBs were treated with melphalan
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and a sIL-6R ELISA completed. No detectable levels of sIL-6R were detected in BMSCs or
HOBs (data not shown). Finally, to evaluate whether IL-6 protein was being degraded more
rapidly in melphalan treated populations of cells, BMSCs and HOBs were treated with
melphalan alone or in combination with cyclohexamide [100ug/ml]. Cycloheximide exposure
resulted in the expected decrease in IL-6 protein over 24 hrs and the addition of melphalan did
not lead to a more rapid degradation of IL-6 protein (data not shown).

Melphalan treatment, compared to other chemotherapeutic agents, resulted in the most
pronounced decrease in IL-6 protein.
Based on the previous data, we investigated if the melphalan-induced decrease in IL-6
protein was specific or if chemotherapeutic agents, in general, led to the same decrease. While
all the different chemotherapeutic agents investigated led to significant changes in IL-6 protein
compared to untreated cells, melphalan treatment consistently led to the most pronounced
decrease in IL-6.

The IL-6 polymorphism does not affect how BMSC respond to melphalan.
An IL-6 polymorphism has been well described in autoimmune and inflammatory
diseases17-20. To evaluate a potential correlation between of the G>C174 IL-6 SNP in BMSCs
treated with melphalan to drug associated changes in IL-6 expression, primary BMSCs were
first genotyped. Two representative cell lines of each SNP were treated with melphalan
[50ug/ml] and an IL-6 ELISA completed. Regardless of genotype, all cell lines had decreased
detection of IL-6 protein with melphalan treatment.

Melphalan treatment decreased IL-6 mRNA
Based on the observation that melphalan decreases IL-6 protein expression, we
investigated changes in IL-6 mRNA expression with melphalan treatment. To determine relative
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IL-6 transcript levels, BMSC and HOB were treated with melphalan [50μg/ml] and real-time
PCR completed. The levels of IL-6 mRNA transcripts increased initially with 4hrs of treatment,
but overall, decreased with melphalan treatment at the 16hr time point. To evaluate if
melphalan treatment altered the stability of IL-6 RNA, BMSCs and HOBs were treated with
melphalan alone or in combination with Actinomycin-D or α-amanitin. Treatment of cells with
Actinomycin-D or α-amanitin in combination with melphalan treatment did not decrease the
stability of IL-6 mRNA (data not shown). Additionally, BMSC and HOB were left untreated or
treated with melphalan [50ug/ml] and cellular fractionation and western blot completed to
determine if there were any changes in the cellular localization of p65, c-jun or C/EBP-β as
transcription factors previously described to be required for optimal IL-6 gene expression8.
There were no changes in the cellular localization of these proteins with melphalan treatment
compared to untreated cells, using Histone 3 (H3) and heat shock protein 90 (Hsp90) as
fractionation controls (data not shown).

Recombinant IL-6 treatment restores IL-6 mRNA levels.
Treatment of BMSC and HOB with melphalan leads to a decrease in IL-6 mRNA. To
evaluate if this decrease in mRNA could be restored, BMSC and HOB were treated with
recombinant IL-6 alone or melphalan alone or in combination with recombinant IL-6. While
melphalan decreased IL-6 mRNA as described earlier, the addition of recombinant IL-6 restored
IL-6 mRNA expression.

Recombinant IL-6 treatment restores IL-6 protein levels.
Based on the results that recombinant IL-6 restored IL-6 mRNA, we determined if the
addition of recombinant IL-6 to melphalan treated BMSC and HOB would restore IL-6 protein
expression. BMSC and HOB treated with melphalan alone had decreased IL-6 protein as
described earlier, and the combination of melphalan and recombinant IL-6 led to significant
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increases in IL-6 protein, with the most pronounced increases at 24 and 48hrs post-treatment.
Control experiments were completed to confirm that the recombinant IL-6 was completely was
rinsed from the cells and not being detected in the ELISA as a residual factor (data not shown).

Discussion
In the current study we investigated the effects of chemotherapy on IL-6 expression in
bone marrow stromal cells and human osteoblast as two representative supportive cells of the
bone marrow microenvironment that influence stem and hematopoietic progenitor cell
development3;21-23 .While the target of dose-escalated chemotherapy or irradiation is a tumor cell
population, it is clear that additional cells are also vulnerable to therapy. Successful stem cell or
bone marrow transplantation following immuno-suppressive or myeloablative chemotherapy is
dependent on the ability of diverse cellular components of the microenvironment to maintain
their functionality, including secretion of soluble factors and expression of cellular adhesion
molecules that are critical for the survival, proliferation, and differentiation of stem and immature
progenitor cells24-29.
Previously mentioned was the damage that bone marrow stromal cells are vulnerable
during aggressive treatment. There has also been much literature describing the effects of
osteoblast functional deficiencies and how they impact hematopoiesis. Work by Visnjic et al
showed defects in hematopoiesis in mice where osteoblast deficiency was induced30. Another
model of osteoblast damage was in a transgenic mouse model using the herpesvirus thymidine
kinase gene under the control of a collagen alpha 1 type I promoter, allowing for lineage specific
expression of the gene in osteoblasts. This targeting allowed for the specific ablation of
osteoblasts by addition of ganciclovir. These mice lost lymphoid, myeloid and erythroid
progenitors in the bone and had significantly decreased HSCs. When osteoblasts were allowed
to recover, a coincident recovery in hematopoiesis occurred as well in the bone marrow. Chitteti
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et al showed that CFU expansion was increased when HSCs were cultured with osteoblasts31.
This suggests that osteoblasts have critical roles in the regulation of hematopoiesis, most likely
through both physical and soluble factors.
We have shown that melphalan treatment decreases IL-6 protein in the absence of
intracellular accumulation, suggesting melphalan induced changes in BMSC or osteoblasts is
not causing dysregulated secretion of IL-6 (Figure 1). IL-6 can signal through both its
membrane receptor as well as a soluble receptor32-34. To confirm that the decrease in IL-6
protein was not due to decreased detection of IL-6, we evaluated if BMSC and HOB expressed
the sIL-6R in culture and if the expression of the sIL-6R changed in response to melphalan.
The sIL-6R was not detected in untreated cells or in cells treated with melphalan, suggesting the
sIL-6R is not interfering with our detection of IL-6 protein in cell supernatants (data not shown).
BMSC and HOB were treated with a variety of agents to determine if the effects of
chemotherapy on IL-6 were specific to melphalan or if all chemotherapeutic agents of diverse
classes resulted in comparable damage. Heterogeneity in the drugs examined is reflected by
VP-16 being a topoisomerase II inhibitor, methotrexate an anti-metabolite, vincristine a tubulin
inhibitor, docetaxel an anti-microtubule agent and carboplatin a heavy metal DNA binding agent.
While all these agents led to significant changes in IL-6 protein compared to cells that were
untreated, melphalan had the most pronounced decrease in IL-6 protein in both BMSC and
HOB (Figure 2). Additional studies are required to determine if this effect is seen with other
alkylating agents.
In addition to our studies evaluating different classes of drugs and their effects on IL-6
levels, we also investigated changes in IL-6 protein associated with an IL-6 polymorphism. The
174 G>C SNP has been well characterized in the setting of auto-inflammatory and autoimmune
diseases and is somewhat controversial in whether or not the genotype is a prognostic factor1720;35

. In general, individuals with a genotype of G/C are thought to have “normal” levels of IL-6 in

their serum and when presented with an immune challenge, IL-6 levels increase and then return
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to normal. Individuals with a G/G genotype are described as having high levels of serum IL-6
and hyper-respond when presented with an immune challenge, while individuals with a C/C
genotype are described as having very low levels of IL-6 in their serum and have a minimal
inflammatory response when presented with an immune challenge20. It was of interest to us if
the genotype of an individual affected a person’s response to chemotherapy. Two BMSC cell
lines of each genotype were left untreated or treated with melphalan. Our data show that
regardless of genotype, all cell lines had decreased IL-6 protein in response to melphalan
(Figure 3). Additionally, the amount of IL-6 detected in untreated cells did not correlate with
genotype as the BMSC genotyped as C/C had the highest levels of IL-6.
Based on observed changes in IL-6 protein in response to chemotherapy, we next
investigated whether the decrease in IL-6 protein was due to changes in mRNA. Our data
showed that melphalan decreased IL-6 mRNA in both BMSC and HOB (Figure 4), suggesting
melphalan may be effecting IL-6 expression at a transcriptional level. We evaluated if
melphalan treatment was decreasing the stability of mRNA through experiments using
actinomycin-D and α-amanitin and determined that melphalan treatment was not affecting the
stability of IL-6 mRNA (data not shown). We also investigated if any of the transcription factors
known to positively regulate IL-6 transcription were being affected by melphalan treatment.
BMSC and HOB were left untreated or treated with melphalan and cellular fractionation and
western blot analysis completed looking at NF-κB (p65), AP-1 (c-jun) and C/EBP-β8. It was not
evident that any of these transcription factors are being affected based on cellular localization
however, this does not address binding efficiently to the DNA during melphalan treatment, which
still needs to be investigated.
Finally, in an effort to evaluate if disrupted IL-6 expression can be restored, BMSC and
HOB were treated with a combination of melphalan and rIL-6. While melphalan treatment alone
decreases IL-6 protein as discussed previously, the addition of rIL-6 with melphalan began to
restore IL-6 mRNA and protein levels (Figure 5 and 6). Administering rIL-6 to patients was
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previously attempted following bone marrow transplant, but the toxicity associated with rIL-6
treatment have prevented its use in a clinical setting36. However, the connection between
melphalan and IL-6 in a clinically relevant setting may be the use of melphalan as first-line
therapy in treatment of multiple myeloma (MM). IL-6, in the setting of MM, is a potent
proliferative and survival factor37 and many attempts have been made to decrease IL-6 in the
bone marrow microenvironment through the use of proteosome inhibitors and anti-IL-6
neutralizing antibodies as part of the therapeutic strategy38. Melphalan, as part of a
chemotherapy regimen for MM, may initially decrease IL-6 in the bone marrow
microenvironment, resulting in myeloma cell sensitivity to chemotherapeutic agents. Work by
Gupta et al and many others has shown that MM cells in contact with BMSC increase the
secretion of IL-6 from the BMSC39-41. By showing that IL-6 levels increase with the addition of
rIL-6 (Figure 5 and 6), this may, in part, mimic what is happening in an in vivo setting, where
MM cells have the ability to restore IL-6 signaling in the microenvironment through cell contact,
thus contributing to relapse of disease.
In conclusion, we have demonstrated that melphalan, more so than other
chemotherapeutic agents tested in the current study, decreases IL-6 mRNA and protein with
decreases not being due to instability of message. We have also shown that the addition of rIL6 partially restores IL-6 mRNA and subsequently, IL-6 protein expression, possibly through
stimulating IL-6 signaling pathways in BMSC or HOB. This finding could be important in the
setting of MM, where IL-6 present in the microenvironment acts as a potent proliferative factor
and contributes to progression of the disease. Additionally, understanding the decrease in IL-6
in the microenvironment caused by chemotherapy treatment is important for normal
hematopoietic and immune system recovery following bone marrow or stem cell transplantation,
as IL-6 affects both myeloid and lymphoid lineages of cell differentiaion. To increase the
translational potential of these findings, the effects of melphalan in vivo need evaluated to
determine if the effects on IL-6 protein are similar or if there is redundancy of the IL-6 family
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members that overcome this deficit during treatment. As previously mentioned, murine IL-6
knock-out models have been described as having hematopoietic deficits, suggesting that the IL6 family members are not completely redundant and that optimal IL-6 levels are required to
sustain hematopoiesis. Overall, understanding the effects of chemotherapeutic agents on a
molecular level can provide insight as to why these agents work in disease settings such as MM
as well as provide an understanding as to why patients receiving treatment with these agents as
part of myeloablative regimens prior to bone marrow or stem cell transplantation have long term
hematopoietic deficits.
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Figure Legends
Figure 1. Treatment of human BMSC and HOB with Melphalan decreases Interleukin-6
secretion. BMSC (A,C) and HOB (B,D) cells were seeded into a 96 well plate in triplicate and
left untreated or were treated with melphalan [50 μg/ml] in complete media for 24 hours. After
24 hours, the media was replaced with complete media and supernatants (A and B) or cells
lysates (C and D) in RIPA buffer were collected at the time points above. An Interleukin-6
ELISA was performed to quantitate changes in the levels of IL-6 protein secreted following
chemotherapy.

Figure 2. Melphalan treatments causes the most pronounced decrease in IL-6 protein.
A). BMSC and B). HOB were treated with different chemotherapeutic agents for 24hrs. After
24hrs, the cells were rinsed, the media replaced, supernatants collected at 24 and 48hrs posttreatment and an IL-6 ELISA completed. The concentration of drug used was the highest
tolerable dose without a decrease in cell viability (data not shown). Melphalan treatment led to
the most pronounced decrease in IL-6 protein in both BMSC and HOB.
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Figure 3. The IL-6 G>C174 SNP does not affect BMSC response to melphalan.
BMSC were genotyped for the presence of the IL-6 polymorphism. Two cell lines from each
genotype were treated with melphalan [50ug/ml] for 24hrs. Following treatment, cells were
rinsed, supernatants collected 24hrs post-treatment and an IL-6 ELISA completed. All BMSC
lines had decreased IL-6 protein, regardless of genotype.

Figure 4. Treatment of BMSC or HOB with melphalan decreases IL-6 mRNA expression.
A). BMSC or B). HOB treated with melphalan (50μg/ml) for 4 or 16 hours. Following treatment,
RNA was isolated and quantitated and real-time PCR completed to evaluate changes in IL-6
mRNA expression in chemotherapy treated cells as compared to their untreated controls treated
controls. Melphalan treatment decreases IL-6 mRNA in both BMSC and HOB.

Figure 5. Addition of rIL-6 restores IL-6 mRNA expression in both BMSC and HOB. A).
BMSC or B). HOB were left untreated or treated with rIL-6 [10ng/ml], melphalan [50ug/ml] or a
combination of rIL-6 and melphalan for 4, 8, 18 or 24hrs. Following treatment, the cells were
collected, RNA isolated and real-time PCR completed for IL-6 mRNA expression. Melphalan
treatment alone decreased IL-6 mRNA, while the combination of rIL-6 with melphalan restored
IL-6 mRNA levels.

Figure 6. Addition of rIL-6 restores IL-6 protein expression in both BMSC and HOB. A).
BMSC and B). HOB were left untreated or treated with rIL-6 [10ng/ml], melphalan [50ug/ml] or a
combination of rIL-6 and melphalan for 24hrs. Following treatment, cells were rinsed, media
replaced, supernatants collected at 2, 4, 6, 8, 24 and 48hrs post-treatments and an IL-6 ELISA
completed. Control experiments were completed to confirm the rIL-6 was being washed out and
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not detected by the ELISA assay (data not shown). rIL-6 combined with melphalan began to
restore IL-6 protein expression at 24 and 48hrs post-treatment compared to melphalan
treatment alone.
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Figure 1. Treatment of human BMSC and HOB with Melphalan decreases
Interleukin-6 secretion.
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Chapter V

General Discussion

The idea of using bone marrow transplantation to cure disease was first described in
1951 when Lorenz et al described how using an animal’s own marrow allowed for survival
following total body irradiation1. The first use of this procedure in humans occurred in 1959
when Thomas and colleagues treated a leukemia patient with total body irradiation and
subsequently provided that patient with an infusion of bone marrow from an identical twin2.
These studies and many other provided the groundwork for using total body irradiation, later in
combination with chemotherapy treatment, and bone marrow transplant for treatment of
disease. Currently, bone marrow or hematopoietic stem cell transplant is used for a variety of
diseases such as multiple myeloma, leukemia, lymphoma, autoimmune diseases, aplastic
anemia etc3. The goal of most of these therapies is eradication of the tumor population, creating
space for the transplanted cells. While hematopoietic stem cell transplantation has a mortality
rate of less than 2 percent for autologous transplant and less than 10 percent for allogeneic
transplant, about 40 percent of patients that receive allogeneic transplants die from
complications related to the transplantation including GVHD, veno-occlusive disease and
infection, emphasizing the need to reduce toxicity of conditioning regimens3.
While advances have been made in therapies to eradicate tumor, significantly less
research has been done to address damage that occurs to the hematopoietic microenvironment
following myeloablative chemotherapy regimens. Studies describing BMSC have shown that
damage by chemotherapy and radiotherapy can affect the ability of the BMSC to self-repair and
leads to decreased numbers of functional immune system cells in the blood, with deficits
persisting years after transplant4;5. Additional studies observed that at 1 year post transplant
61% of patients have subnormal values in one or more hematopoietic lineages6. Further,
Nieboer et al. showed that at 5 years post transplant 15% of the patient population analyzed
had low values in one or more hematopoietic cell lineages7. Galotto et al completed
retrospective studies of patients that received allogeneic bone marrow transplants and
determined patient BMSC did not recover to the levels of control patients, even after 12 years,
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as measured by colony forming units-fibroblast (CFU-F) frequencies, suggesting that the
damage of the structural, hematopoietic supportive cells of the bone marrow can be sustained8.
Osteoblasts, another important structural component of the bone marrow in addition to BMSC,
have also been studied for their importance in maintenance of hematopoiesis. These studies
have included transgenic models where osteoblast deficiency was induced by actively targeting
and ablating the osteoblasts9 or using models where the osteoblast niche was manipulated by
knock-out of critical factors such as osteopontin or the osteoblast niche was increased through
the use of parathyroid hormone, leading to decreased and increased hematopoiesis,
respectively10-12.
The broad goals of the work presented in this dissertation were to gain a better
understanding of chemotherapy-induced damage occurring to the cells of the bone marrow
microenvironment and how this damage would affect hematopoietic recovery through evaluation
of an in vitro co-culture model.
Previous work by our lab has characterized damage to BMSC and has shown increases
in active TGF-β following chemotherapy treatment13. TGF-β, as previously discussed, is an
important factor in supporting and maintaining quiescent hematopoietic stem cells14. It has
been proposed that this could lead to depletion of the stem cell pool. We evaluated the effects
of chemotherapy on osteoblasts to determine how both direct and indirect chemotherapy
exposure may lead to damage of the osteoblast population. As we discussed in Chapter 1,
human primary osteoblasts were treated with melphalan and VP-16 and we evaluated changes
in soluble factors, cellular adhesion molecules and overall support of both human embryonic
stem cells and CD34+ bone marrow cells. Treatment of osteoblasts with chemotherapy led to
slight increases in TGF-β mRNA and active TGF-β, evaluated by phosphorylation of Smad2.
Additionally, chemotherapy treatment led to decreases in CXCL12 mRNA and protein and
decreased chemotaxis. We also evaluated the effects of recombinant TGF-β (rTGF-β), to mimic
both autocrine and paracine signaling associated with chemotherapy-induced changes.
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Treatment of osteoblasts with rTGF-β led to increased TGF-β mRNA and protein and decreased
CXCL12 mRNA and protein, coincident with decreased chemotaxis. To determine functional
changes in the ability of damaged osteoblasts to support stem cells, hESC and CD34+ bone
marrow cells were cultured on osteoblasts pre-treated with chemotherapy or rTGF-β. In both
circumstances, hESCs did not retain Oct-4 expression, a marker of pluripotency, and CD34+
cells had deficits in their ability to differentiate into different hematopoietic cell lineages. These
data suggest that osteoblasts are a population of cells that are vulnerable to chemotherapy
damage, and hematopoiesis could be negatively affected through damage to the
microenvironment. One way to help restore this environment might be through the use of cotransplantation of MSCs as a mechanism to “rebuild” the microenvironment. Additionally, one
could speculate that factors leading to the differentiation of osteoblasts, BMSC and the other
cell types of the microenvironment could be administered to stimulate differentiation of MSCs
already present in the microenvironment to functionally supportive cells.
Another soluble factor investigated in the studies presented was Interleukin-6 (IL-6) as a
factor important in the differentiation of both myeloid and lymphoid lineages15. Initially, we
expected that chemotherapy treatment of BMSC or osteoblasts would lead to increases in IL-6,
as it has been a factor associated with acute graft versus host disease16. We actually
determined that chemotherapy treatment, melphalan specifically, led to decreases in IL-6
protein and mRNA in both BMSC and HOB (Chapter 3). Compared to other chemotherapeutic
agents evaluated in this study, melphalan had the most pronounced effect. To evaluate if IL-6
mRNA and protein levels could be restored in an autocrine fashion, we combined melphalan
treatment with recombinant IL-6. Both mRNA and protein levels were restored in these
combination treatment groups. This was an important observation relevant to multiple myeloma
(MM). In MM, IL-6 is a proliferative factor for the myeloma tumor cells and work by Gupta et al
and Barille et al have shown that myeloma cells, directly in contact with BMSC and osteoblasts ,
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can upregulate IL-6 expression17;18 and Westendorf et al described how myeloma cells
themselves could secrete IL-6 and engage in autocrine signaling19. Melphalan, along with other
agents, is first-line therapy for the treatment of MM. The decrease of IL-6 in BMSC and
osteoblasts by melphalan could help to explain why this chemotherapeutic agent has effects in
MM. By decreasing IL-6 in the microenvironment, the myeloma cells may be more sensitive to
chemotherapy. By showing in vitro that that addition of rIL-6 could restore IL-6 levels, this may,
in part, explain how in vivo, the tumor is able to restore IL-6 secretion in the bone marrow
microenvironment allowing for relapse of disease. The cytokine profile and recovery dynamics
in vivo is important in understanding how prolonged the decrease in IL-6 and other
hematopoietic cytokines is. Studies by Testa et al have looked at hematopoietic growth factors
(IL-3, SCF, IL-6, IL-8 and GM-CSF) in patient serum pre and post-chemotherapy, and have
shown how these factors increase or decrease following chemotherapy20. The
chemotherapeutic agents used for these studies were busulphan and cyclophosphamide, so
similar experiments in patients treated with a melphalan regimen would be useful in
understanding differences in cytokine recovery profiles with different chemotherapy regimens to
determine optimal schedules for infusion of hematopoietic stem and progenitor cells.
Additional studies presented in this proposal related to IL-6 have a focus on the
neuroendocrine modulation of the bone marrow21. Studies have shown that NGF has roles in
colony formation22;23 and in a model using stromal cells isolated from the thymus, it was shown
that NGF increased IL-6 expression24. The role of BDNF in hematopoiesis was also studied
using a BDNF knockout mouse and it was demonstrated that the number of B lymphocytes both
in the spleen and the bone marrow were decreased25. These data suggest that neurotrophins
have much broader paracrine effects than just in the central nervous system. In chapter 2 of
this dissertation, we have shown that primary BMSC express neurotrophin receptors and that
these receptors can actively signal following stimulation with NGF or BDNF, and using
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phosphorylated Akt as a read-out of signaling. Treatment of BMSC with NGF or BDNF also led
to increases in both IL-6 mRNA and protein and we determined that the mechanism of this
increase of IL-6 by neurotrophins was through the MAPK pathway. One could speculate that
injury to the central nervous system, possibly by total body irradiation as part of a myeloablative
pre-transplant regimen, could lead to the increase of the neurotrophic factors. This potential
increase in neurotrophins could have paracrine effects in the bone marrow, leading to increases
in IL-6. Increases in IL-6 are associated with a number of inflammatory diseases such as
systemic lupus erythematosus and rheumatoid arthritis26 and IL-6 has also been implicated in
acute graft versus host disease16 so it is possible that increased neurotrophins could lead to
dysregulated hematopoiesis.
In conclusion, the data presented here have allowed for an appreciation of not only the
complexity of the bone marrow microenvironment, but also the dynamic nature of the supportive
cells, namely BMSC and HOB, and how chemotherapy affects other cell populations in addition
to the tumor population. While many studies have been done showing BMSC are affected by
chemotherapy, very few, if any studies have attempted to understand the mechanisms by which
that damage is occurring to another critical component, marrow osteoblasts. Understanding the
mechanisms by which chemotherapy damages the supportive cells of the bone marrow cells
can help with the development of therapies that could help restore the microenvironment
following aggressive chemotherapy, like the use of MSCs as a way to help “rebuild” the
microenvironment. While in vitro models provide a way to study mechanisms of damage, it is
critical to complete additional experiments in an in vivo model to further understand if the effects
of chemotherapy described are also present in vivo or if redundant signaling pathways blunt
these effects. Collaborations with clinicians are also vital to ensure that basic science questions
are being addressed in such a way that they are translatable to a clinical setting.
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